BDNF signaling in epilepsy: TRKB-induced JAK/STAT pathway and phosphorylation of LSF in neurons by Hokenson, Kristen Elizabeth
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2016
BDNF signaling in epilepsy:
TRKB-induced JAK/STAT pathway
and phosphorylation of LSF in
neurons
https://hdl.handle.net/2144/16740
Boston University
	BOSTON UNIVERSITY 
SCHOOL OF MEDICINE 
 
Dissertation 
 
BDNF SIGNALING IN EPILEPSY: TRKB-INDUCED JAK/STAT PATHWAY 
AND PHOSPHORYLATION OF LSF IN NEURONS 
 
by 
KRISTEN ELIZABETH HOKENSON 
B.A., Smith College, 2007 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy 
2016 
	 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     ©   Copyright by 
           KRISTEN ELIZABETH HOKENSON 
           2016 
	Approved by 
 
First Reader             ________________________________________________ 
Shelley J. Russek, Ph.D. 
Professor of Pharmacology and Biology 
Director of Graduate Program for Neuroscience 
 
Second Reader       ________________________________________________ 
Ulla Hansen, Ph.D. 
Professor of Biology 
Director of Program in Molecular Biology, Cell Biology, and  
 Biochemistry 
 
  
	 iv	
DEDICATION 
 
 
 
 
To my family and friends, my dog, and my late father 
For their unconditional love and support 
  
	 v	
ACKNOWLEDGEMENTS 
 
To my late father, John, who was always there for me. I love and miss you. 
 
To my mother, Jan, and my brother, Andrew, my biggest fans. Thank you for 
always supporting me. I love you. 
 
To all my friends, who have supported my from afar and made Boston my 
second home for the past years. I could not have done this without you. 
 
To my dog, Toby, my little rock. I love you. 
 
To my mentor, Dr. Shelley Russek, for believing in me, listening to me, and 
challenging me. Thank you for your kindness and guidance over the years. 
 
To our collaborators, Dr. Hansen, Dr. Brooks Kayal, Dr. Barker, and Dr. Levine, 
for kindly providing me with the tools I needed to drive my research forward. 
 
To my thesis committee members, Dr. Ikezu, Dr Cui, and Dr. Moss, for their 
enthusiasm and input for my research. Thank you for your help and support. 
 
	 vi	
To Dr. Farb and Dr. Walsh, for the opportunities they have provided through the 
Pharmacology department. 
 
To Wanda, Nadiyah, and Sara, for all their help. Thank you for always knowing 
the answers to all my questions. 
 
To Sabita, for all that you do. It has been such a pleasure working with you. 
 
To my lab buddies, old and new, Julia, Meaghan, Zhuting, Becky, and Kathryn. I 
don’t know what I would have done without you. I have so many great memories 
and made friends for life. Love you all! 
 
To Greg, for your enthusiasm and help. 
 
To the Pharmacology department students and friends, best of luck! 
  
	 vii	
BDNF SIGNALING IN EPILEPSY: TRKB-INDUCED JAK/STAT PATHWAY 
AND PHOSPHORYLATION OF LSF IN NEURONS 
 
 
KRISTEN ELIZABETH HOKENSON 
Boston University School of Medicine, 2016 
Major Professor:   Shelley J. Russek, Ph.D., Professor of Pharmacology and  
   Biology, Director of Graduate Program for Neuroscience 
 
ABSTRACT 
Epilepsy is a neurological disorder that causes recurrent and unprovoked 
seizures due to imbalances in synaptic transmission in distinct regions of the 
brain. In both human patients and animal models of epilepsy, there is a marked 
increase in brain-derived neurotrophic factor (BDNF), a critical signaling molecule 
in the brain that contributes to two divergent pathways important to disease 
pathology: 1) the regulation of type A receptors for the major inhibitory 
neurotransmitter GABA (GABAARs), and 2) aberrant neurogenesis with ectopic 
expression of new neurons from progenitor cells that disrupt neural network 
activity in the hippocampus. The first part of my thesis addresses how neurons 
regulate levels of α1-containing GABAARs through BDNF signaling at its 
receptors, tropomyosin receptor kinase B (TrkB) and p75 neurotrophin receptor 
(p75NTR). I hypothesized and showed that BDNF, working at TrkB, rapidly 
	 viii	
activates the Janus kinase and signal transducers and activators of transcription 
(JAK/STAT) pathway in neurons and identified a novel intracellular receptor 
signaling complex composed of p75NTR and JAK2 that is present in neuronal 
processes, cell body, and nucleus. Based on this finding, we suggest that an 
intracellular p75NTR/JAK2 signalsome recruits STAT3, a transcriptional activator 
of the gene coding for the cAMP inducible early repressor (ICER) that blocks 
synthesis of α1 subunits reducing synaptic GABAARs in response to status 
epilepticus. This model is consistent with our collaborative studies that show a 
JAK2 inhibitor, WP1066, inhibits development of spontaneous seizures in an 
epilepsy model and my observation that WP1066 degrades JAK2 protein in 
primary neurons. The second part of my thesis addresses BDNF regulation of the 
Late SV40 Factor (LSF), a ubiquitous transcription factor that regulates cell cycle 
progression and survival. I show that BDNF through the mitogen-activated 
protein kinase pathway selectively phosphorylates LSF at serine 291 (p291LSF) 
and that p291LSF is present throughout neurogenesis, increases with status 
epilepticus in the hippocampus, and is highest in structures associated with 
neurogenesis (such as olfactory bulb and hippocampus when compared to 
cortex). Taken together, these results suggest LSF may play an important role in 
neuronal development and potentially in epilepsy, providing an additional target 
for future therapeutic intervention. 
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I. INTRODUCTION 
A. Epilepsy 
1. Epilepsy Background and Definition  
 
Epilepsy is a neurological disorder that affects over two million people in 
the United States, with an estimated 150,000 new cases diagnosed every year 
(Epilepsy Foundation, 2014). Fisher et al. (2005) previously defined epilepsy as a 
brain disorder characterized by a lasting predisposition to generate epileptic 
seizures and by the neurobiologic, cognitive, psychological, and social 
consequences of this condition, requiring the occurrence of at least one epileptic 
seizure. The operational definition of epilepsy has recently been updated as a 
brain disorder consisting of either two or more unprovoked seizures occurring 
more that 24 hours apart, or one unprovoked seizure and a probability of further 
seizures similar to the general recurrence risk (at least 60%) after two 
unprovoked seizures occurring over the next ten years, or diagnosis of an 
epilepsy syndrome (Fisher et al., 2014).   
Seizures are periods of abnormal, synchronous excitation of a neuronal 
population likely caused by a disruption of the balance of excitatory and inhibitory 
neurotransmission, and can last seconds to minutes, or can be continuous and 
prolonged. A disturbance in the resting membrane potential of neurons could 
contribute to seizures, as is evidenced by studies showing that seizures can be 
caused by both the blockage of sodium-potassium ATPase (Vailland et al., 2002) 
and mutations that modulate the function of voltage-dependent sodium channel 
		 2	
(Meisler et al., 2001). Seizures may also result from changes in synaptic 
transmission of the major inhibitory and excitatory neurotransmitters, γ-
aminobutyric acid (GABA) and glutamine, respectively. Synchronization of 
neuronal networks, or the abnormal firing of neurons together, is also involved in 
seizure activity. This synchronization is thought to be a result of glutamatergic 
interconnections (Brown and Johnson, 1984), gap junctions (Traub et al., 2004), 
or GABAergic interneurons (Cobb et al., 1996) that are able to connect groups of 
cortical neurons. 
Epilepsy is marked by recurrent seizures, and has a separate 
neurobiology from seizures due to underlying structural and functional 
abnormalities. Epilepsy may result from genetic causes (Meisler et al., 2001; 
Ottman, 2005), developmental disorders or malformations (Lehericy et al., 1995; 
Baulac et al., 1998; Ho et al., 1998), and a response to injury or insult, none of 
which are mutually exclusive (Lewis, 2005). In a majority of epilepsy cases, 
however, the cause is unknown. The most identifiable cause of epilepsy is from 
an initial insult, such as traumatic brain injury (TBI) or infection. Initial episodes 
are commonly followed by a latent period before the development of 
spontaneous seizures. Many studies have aimed to discover the molecular 
changes that occur during this latent period, as this may help to uncover the 
mechanism(s) underlying the development of epilepsy, referred to as 
epileptogenesis. The development of novel therapeutics is critical, considering 
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that one third of people with epilepsy does not respond to any current treatments 
and are therefore refractory to intervention.    
2. Types of Seizures  	
 There are many different types of seizures and a person with epilepsy can 
manifest more than one type of seizure. Seizures are classified into two groups: 
primary, or idiopathic, generalized seizures affect both sides of the brain, while 
focal, or partial, seizures affect one area of the brain (Kandel et al., 2000). 
Generalized seizures are genetic in etiology and include absence and tonic-
clonic seizures. Absence, or petit mal, seizures cause rapid blinking or staring 
into space, while tonic-clonic seizures, or grand mal, can cause patients to cry 
out, lose consciousness, fall, or have muscle jerks and spasms, or tiredness after 
the seizure event (Brunton et al., 2005). Focal seizures are typically the result of 
a cerebral insult, which is unknown in a majority of cases. There are three types 
of focal seizures: simple seizures, which affect a small part of the brain and can 
cause twitching or a change in sensations such as taste or smell; complex focal 
seizures, which can cause confusion or daze, during which people are unable to 
respond to questions or directions for up to a few minutes; secondary 
generalized, or partial onset with secondary generalization, begin as a focal 
seizure in one part of the brain, followed by a generalized seizure by spreading to 
both sides of the brain (Brunton et al., 2005). If left untreated, prolonged seizures 
with convulsions may cause immediate and permanent injury or death. (Epilepsy: 
Epidemiology, Etiology, and Prognosis, n.d.) 
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3. Refractory and Temporal Lobe Epilepsy 	
About 60-75% of epilepsy cases involve focal seizures and more than half 
of these patients experience complex partial seizures (Alving, 1978; Banerjee 
and Hauser, 2008). Half of these cases cannot be controlled with medication 
while the other half have seizures despite being on antiepileptic drugs, or 
experience significant side effects from medications. Cases of epilepsy are 
considered refractory when two are more antiepileptic drugs have failed to 
control the seizures (Berg and Shinnar, 1991; Kwan and Brodie, 2000). 
Temporal lobe epilepsy (TLE) is the most common form of refractory 
epilepsy and is characterized by complex partial seizures originating in the limbic 
system and hippocampus (Wieser et al., 1993). There is strong evidence that the 
major predisposing factor for epileptogenesis is a rise in brain derived 
neurotrophic factor (BDNF) that signals through two receptors, tropomyosin 
receptor kinase B (TrkB) and P75 Neurotrophin Receptor (P75NTR). Increased 
levels of BDNF mRNA and protein occur in the hippocampus and temporal lobe 
of human epileptic brains (Takahashi et al., 1999), and neocortical tissue from 
epileptic patients has increased levels of TrkB, the high affinity BDNF receptor, 
compared to control patients (Wyneken et al., 2003). Protein and mRNA levels of 
BDNF is also increased in many animal models of epilepsy, including kindling 
(Ernfors et al., 1991; Elmer et al., 1998), kainic acid (Rudge et al., 1998), and 
pilocarpine (Mudo et al., 1996; Poulsen et al., 2004; Roberts et al., 2006).  
Recent studies from the laboratories of Dr. David Ginty (Harvard University) and 
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Dr. Jim McNamara (Duke University) using a chemical genetic mouse model for 
the reversible and specific silencing of TrkB (Chen et al., 2005) now provide 
evidence for a direct role of TrkB signaling in the development of spontaneous 
seizures in models of TLE (Liu et al., 2013). How BDNF orchestrates the 
remodeling of the brain into an epileptic phenotype still remains a mystery and is 
the subject of many research programs.  
4. Animal Models of Epilepsy 	
Chemoconvulsants 
 Treatment with the chemoconvulsants pilocarpine and kainic acid can lead 
to spontaneous seizures in rodents (Leite et al., 2002). These are good models 
for TLE because rodents follow a similar clinical manifestation: An initial insult to 
the hippocampus and/or temporal lobe, known as status epilepticus (SE), 
followed by a latent period before the development of chronic partial and tonic-
clonic spontaneous seizures, and histopathological changes (Kandratavicius et 
al., 2013c; Mathern et al., 2002; Lothman and Bertram, 1993).   
 When injected systemically or intracerebrally, kainic acid, an L-glutamate 
analog, causes neuronal depolarization and seizures, mainly in the hippocampus 
(Nadler et al., 1978). Kainic acid causes recurrent secondarily generalized 
seizures of variable frequency in rodents, as well as histopathological 
hippocampal sclerosis (Raedt et al., 2009). Kainic acid injuries are restricted to 
the hippocampus, while pilocarpine produces lesions in neocortical areas 
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(Sharma et al., 2007), which is similar to human TLE pathology (Bonilha et al., 
2010), making pilocarpine a useful chemoconvulsant model. 
 Pilocarpine, a muscarinic acetylcholine receptor agonist, is also injected 
systemically or intracerebrally and causes seizures that build into a limbic SE 
(Furtado et al., 2002; Turski et al., 1983). The pathology and development of 
spontaneous seizures is similar to human complex partial seizures (Cavalheiro et 
al., 1991), and antiepileptic drugs (AEDs) that treat complex partial seizures in 
humans can stop spontaneous seizures in the pilocarpine model (Leite and 
Cavalheiro, 1995). There are many similarities between human TLE and the 
pilocarpine model, including interictal activity in the subiculum (Knopp et al., 
2005), and upregulation of neurotrophins in the hippocampus of both mesial TLE 
patients (Kandratavicius et al., 2013a) and pilocarpine-treated rats (Mudò et al., 
1996). Cognitive and memory deficits seen in TLE patients (Kandratavicius et al., 
2013b; Pauli et al., 2006) are also present in pilocarpine-injected rats (Leite et al., 
1990; Faure et al., 2014). 
Electrical stimulation 
 Electrical stimulation can also induce seizures in animal models, but does 
not provide cell-specificity in the brain (Pitkänen et al., 2006). Electroshock 
induced seizures (ES) are induced after a single, whole-brain stimulation. 
Minimal ES is a model of myoclonic seizures, which can cause muscle jerks and 
twitching, and forebrain epileptiform activity (Löscher and Schmidt, 1988), while 
maximal ES is a model for generalized tonic-clonic seizures, with hindbrain 
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seizures (Browning and Nelson, 1985). Single-evoked epileptic afterdischarges 
are evoked using electrical stimulation in specific brain regions, and resemble 
complex partial seizures if applied to the limbic system or myoclonic seizures if 
applied to the sensorimotor cortex (Sloan et al., 2011; Velísek and Mareš, 2004). 
Afterdischarges (ADs) are commonly induced in the hippocampus (Kotloski et al., 
2002; Norwood et al., 2010), which is followed by postictal refractory period 
before subsequent seizures (Velísek and Mareš, 2004).    
Kindling  
 Kindling is a seizure-induced plasticity caused by repeated afterdischarge 
induction by electrical stimulation, ultimately leading to increased seizure 
susceptibility, spontaneous seizures, and chronic epilepsy (Goddard et al., 1969). 
Unlike kainic acid and pilocarpine induced TLE models, which have initial severe 
SE that causes temporal and extratemporal damage and rapid development of 
spontaneous recurrent seizures (Sutula, 2004), kindling produces small and 
cumulative neuronal loss and cellular alterations in the brain that eventually result 
in spontaneous seizures (Sayin et al., 2003).  
5. Antiepileptic Drugs 	
 Antiepileptic drugs (AEDs) do not cure or prevent epilepsy, but instead 
treat the major symptom of epilepsy by supressing seizures. AEDs suppress 
seizures through three main mechanisms: modulating voltage-gated ion 
channels, enhancing GABA-mediated inhibitory neurotransmission, and 
attenuating glutamate-mediated excitatory neurotransmission.  
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Voltage-gated sodium channel modulators 
 Certain mutations of sodium channels can lead to familial forms of 
epilepsy (Catterall et al., 2008) and the most commonly used AEDs act on 
voltage-gated sodium channels. Voltage-gated sodium channels have three 
basic conformational states: resting, open, and inactivated. During neuron 
depolarization, channels cycle through these states in the order resting to open, 
open to inactivated, inactivated to resting, and are unresponsive to further 
depolarization until most channels have returned to resting state from the 
inactivated state (Hille, 1992). AEDs are able to block sodium channels due to 
their high affinity for the channel in the inactivated state, where they bind and 
slow the conformational recycling process. These drugs reduce channel 
conductance in a voltage and frequency-dependent manner, limiting repetitive 
neuronal firing, with little effect on the generation of single action potentials (Levy 
et al., 2002). There are multiple inactivation pathways that add complexity to the 
mechanism of action, with most sodium channel blocking AEDs targeting the fast 
inactivation pathway. Evidence shows that lacosamide and eslicarbazepine 
acetate may enhance slow inactivation (Hebeisen et al., 2015). Phenytoin, 
carbamazepine, and valproic acid are sodium channel blockers that effectively 
reduce frequency of partial seizures (Mattson et al., 1985; Mattson et al., 1992), 
and share a common mechanism with newer drugs, lamotrigine, felbamate, 
topiramate, oxcarbazepine, zonisamide, rufinamide, lacosamide, and 
eslicarbazepine acetate. Tonic–clonic seizures are commonly treated with 
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valproic acid, phenytoin, or carbamazepine (Levy et al., 2002). Evidence also 
suggests that gabapentin has inhibitory effects on neuronal sodium channels 
(Wamill and McLean, 1994). Phenytoin, a popular AED, is able to control 
convulsive seizures in both idiopathic generalized epilepsy and focal epilepsy 
with secondarily generalized tonic-clonic seizures (Stern et al., 2008). 
Calcium channel modulators 
 The voltage-gated calcium channel, which is involved in neuronal 
excitability, burst firing, and controls pre-synaptic neurotransmitter release, is a 
common target for AEDs. Calcium channels open from their closed state when 
the membrane potential depolarizes to threshold, conduct ions in the open state, 
and inactivate with ongoing depolarization. Inactivated channels reopen by 
hyperpolarized membrane potentials, to a state of de-inactivation, where 
membrane depolarization can reopen the channels. Calcium channels are 
generally slower at opening and closing than voltage-activated sodium channels. 
High voltage-activated (HVA) channels are slower activating, faster deactivating, 
and slower inactivating than low voltage-activated (LVA), or T-type channels. 
HVA channels generate long lasting calcium influxes with sustained 
depolarization, with T-type channels able to conduct more rapid and shorter 
calcium influxes under depolarization (Reviewed by Cain and Snutch, 2012). 
 Ethosuximide and zonisamide, treatments for generalized absence 
epilepsy, block the LVA T-type calcium channel (Hughes, 2009), an effect also 
shown by sodium valproate (Kelly et al., 1990). Lamotrigine blocks N and P/Q 
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type HVA calcium channels (Stefani et al., 1996) and partially bocks N-type 
calcium currents (Wang et al., 1996), which limits neurotransmitter release. 
Phenobarbital, felbamate, and topiramate affect HVA calcium channel 
conductance, though this effect is not well characterized (Kwan et al., 2001; 
Rogawski and Löscher, 2004). Gabapentin and pregabalin also work via HVA 
calcium channels by binding to an accessory subunit (α2δ-1), which modulates 
the function of various channels (Dooley et al., 2007).  
Voltage-gated potassium channel modulators 
 Potassium channels are the major regulators of the electrical properties of 
neurons and responsiveness to synaptic inputs (Shieh et al., 2000). Increased 
membrane conductance to potassium (K+) ions causes hyperpolarization and 
reduction in firing frequency, which inhibits neuronal excitability. The M-current 
(IKM), a low-threshold, slowly activating and deactivating, and noninactivating 
voltage-dependent K+ current, limits repetitive firing and causes spike frequency 
adaptation (Rogawski, 2000). The Kv7 (KCNQ) subfamily of K+ channel genes 
contains five members, four of which (Kv7.2 through Kv7.5) are expressed in the 
nervous system. Mutation studies have shown that Kv7.2 and Kv7.3 are involved 
in brain excitability control and seizure activity (Bellini et al., 1993-2010; Peters et 
al., 2005; Watanabe et al., 2000). The antiepileptic drug retigabine activates and 
opens the Kv7 subfamily of voltage-gated potassium channels, which enhances 
the M-current, increases the rate of activation by depolarization, and decreases 
the rate of deactivation. It also enhances the M-current at resting membrane 
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potential, which hyperpolarizes the cell membrane and reduces neuronal 
excitability (Barrese et al., 2010). 
Glutamate receptor modulators 
 Glutamate, the principal excitatory neurotransmitter in the mammalian 
brain, binds to three subtypes of ionotropic glutamate receptor (iGluR) in the 
postsynaptic membrane, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPA), kainate, and N-Methyl-D-aspartic acid (NMDA), increases 
cation conductance and depolarizes the neuron (Dingledine et al., 1999). AMPA 
receptors (GluA1-GluA4) mediate most of fast excitatory synaptic transmission 
and are permeable to sodium (Na+) and potassium (K+) ions, with GluA2-lacking 
receptors also permeable to calcium (Ca+) ions. AMPA receptor inhibitors, such 
as perampanel, may be an effective adjunctive treatment for drug-resistant 
partial-onset seizures (Krauss et al., 2012). NMDA receptors (GluN1, GluN2A-
GluN2D, GluN3A, and GluN3B) are cationic channels permeable to Na+, K+, and 
Ca2+ ions (Perez-Otano and Ehlers, 2005). Felbamate is an effective AED 
(Sachdeo et al., 1992) that inhibits NMDA-evoked responses of GluN2B-
containing NMDA receptors (Sofia, 1994), whose expression changes in epilepsy 
(Mathern et al., 1998). Other NMDA-antagonist AEDs include remacemide 
(Subramaniam et al., 1996; Norris & King, 1997), losigamone (Srinivasan et al., 
1997), and Huperzine A (Zhang et al., 2002). Kainate receptors (GluK1–GluK5) 
modulate synaptic transmission and neuronal excitability both as ionotropic 
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receptors and by linking to metabotropic signaling pathways (Rodriguez-Moreno 
& Lerma, 1998), but there are no AEDs that act mainly on kainate receptors. 
GABA receptor modulators 
 The major inhibitory neurotransmitter in the central nervous system (CNS), 
γ-aminobutyric acid (GABA) is released into the synapse when neurons 
depolarize and binds to post-synaptic ionotropic GABAA and metabotropic 
GABAB receptors, causing hyperpolarization (Rowley et al., 2012). The ionotropic 
GABAA receptor (GABAAR) contains binding sites for benzodiazepines (BZs), 
barbiturates, neurosteroids, general anesthetics, loreclezole, and convulsant 
toxins, picrotoxin and bicuculline. Many AEDs bind and activate GABAAR, 
enhancing the GABA response. Barbiturates, including phenobarbital and 
primidone, and BZs, including diazepam, clobazam, and clonazepam, have this 
effect, but bind to different receptor sites and differentially affect the opening of 
the chloride (Cl−) ion pore (Greenfield Jr, 2013). GABAARs are made up of five 
subunits out of 16 different α, β, γ, δ, π, ɛ, and θ subtypes (detailed in “GABAA 
Receptors” section) and composition can determine the specifity of modulators 
(Pritchett et al., 1989; Wingrove et al., 1994; Draguhn et al., 1990). BZs are 
agonists of γ subunit-containing (Macdonald and Olsen, 1994) GABAARs that 
increase the frequency of channel opening (Study and Barker, 1981; Rogers et 
al., 1994), and are most effective against convulsive seizures (Rogawski and 
Porter, 1990) and kindling (Swinyard and Castellion, 1966). Barbiturates prolong 
the opening of GABAARs (Eadie and Kwan, 2008) and are effective for focal, 
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myoclonic and convulsive seizures of idiopathic generalized epilepsies (Fincham 
and Schottelius, 2002). Loreclezole prevents seizures in a variety of models, acts 
like a barbiturate by prolonging GABAAR opening (Ashton et al., 1992).  
Ganaxolone, an analog of the neurosteroid allopregnanolone and a natural 
metabolite of progesterone, allosterically enhances GABAAR current (Carter et 
al., 1997) by increasing the proportion of GABAAR openings (Twyman and 
Macdonald, 1992) and is may be effective for partial onset seizures (Monaghan 
et al., 1999). Newer AEDs, including topiramate, felbamate, retigabine, 
losigamone, and stiripentol, modulate GABA responses at the GABAAR and have 
other anti-seizure targets, but their mechanisms and binding sites are unknown 
(Greenfield Jr, 2013). GABA synthesis and metabolism may be affected by 
gabapentin (Taylor, 1997; Löscher et al., 1991), pregabalin (Nemeroff, 2003) and 
valproic acid (Löscher, 1982). Other mechanisms of AEDs include blockage of 
GABA reuptake by tiagabine (Frahm et al., 2001), inhibiting GABA catalysis by 
vigabatrin (Richens, 1991). 
Ketogenic Diet 
 An alternative treatment to AEDs, especially in children, is the high-fat 
ketogenic diet (KD), which causes production of ketone bodies, such as, β-
hydroxybutyrate (BHB), acetoacetate (ACA), and acetone, by the liver 
(Peterman, 1924).  The currently used KD has been modified to the medium-
chain triglyceride (MCT) diet, and is used as an alternative dietary option for 
medically intractable epilepsy (Huttenlocher et al., 1971; Neal et al., 2009).  
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Ketone bodies are energy metabolites that may act as anti-seizure agents by 
regulating neurotransmission or ion channels, enhancing mitochondrial function, 
reducing oxidative stress, and restricting glycolysis (Rho, 2015), which could 
affect gene expression of BDNF and TrkB (Garriga-Canut et al., 2006). 
B. GABAA Receptors  
1. GABAA Receptor Structure and Function 
 GABA synthesis from glutamic acid (glutamate) is catalyzed the enzyme 
glutamate decarboxylase (GAD) (Schousboe et al., 2013a; Saito et al., 1974) and 
requires the synthesis of glutamine from glucose in astrocytes, which is catalyzed 
by pyruvate carboxylase, the tricarboxylic acid (TCA) cycle, and glutamine 
synthetase (GS) (Norenburg and Martinez-Hernandez, 1979; Yu et al., 1983). 
GABA is packed into vesicles with vesicular GABA transporters (VGAT) (McIntire 
et al., 1997), which release GABA into the synapse upon depolarization, allowing 
GABA to bind to post-synaptic GABAA and GABAB receptors and hyperpolarize 
the post-synaptic neuron (Rowley et al., 2012). GABA neurotransmission is 
inactivated by the uptake of GABA via GABA transporters (GATs) on the 
presynapse, where a majority of released GABA ends up, or astrocytes (Rowley 
et al., 2012; Shousboe et al., 2013b). 
 GABA acts as an agonist on the type A receptor for GABA (GABAAR). 
GABAARs, with glycine receptors, are the major inhibitory ligand-gated anion-
selective ion channels and belong to the Cys loop ligand-gated ion channel 
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superfamily (Betz, 1990; Miller and Smart, 2010). The protein structure of GABAA 
receptors consists of a pentamer of different subunits (Macdonald and Olsen, 
1994; Nayeem et al., 1994). Sixteen subunit subtypes have been cloned in 
mammals, including six α, three β and three γ subtypes, δ, π (Hedblom and 
Kirkness, 1997), ɛ (Davies et al., 1997) and θ (Bonnert et al., 1999), as well as β2 
and γ2 subtype splice variants. The expression of these subunits differs based 
on region, type of cell (Wisden et al., 1992), and stage of development (Brooks-
Kayal et al., 1998a), with the most common composition being two α1, two β2 
and a single γ2 subunit, and extrasynaptic receptors expression the δ subunit 
instead of γ. Each subunit is about 450 amino acids, and half of each subunit 
consists of a hydrophilic extracellular N-terminal domain, which contains the Cys 
loop, followed by four transmembrane sequences (M1–M4). M2 lines the ion 
channel, while M3 and M4 is a large intracellular loop involved in modulation by 
phosphorylation. The subunits surround a water-filled pore, providing a gate to 
conduct Cl− ions when two molecules of GABA are bound to the receptor 
(Sakmann et al., 1983). 
 A single cell may contain a diverse population of GABAARs, and in some 
cases more than eight subunit isoforms are expressed in one neuron (Sigel and 
Steinmann, 2012). Receptor diversity depends on alternative splicing and RNA 
editing (Daniel and Ohman, 2009). There are about 30 possible pentameric 
receptors and the same subunits may be arranged differently to form different 
receptors (Sigel and Steinmann, 2012). The α, β, and γ subunits seem to 
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combine into defined subunit arrangements (Tretter et al., 1997; Baumann et al., 
2002; Baur et al., 2006) while the ε and δ subunits have promiscuous assembly 
properties (Bollan et al., 2008; Kaur et al., 2009; Baur et al., 2009). Subunit 
composition (Sigel et al., 1990) and arrangement (Minier and Sigel, 2004) 
determine the functional properties of the receptors.  
2. GABAA Receptor Changes in Epilepsy 	
 Animal models of epilepsy show alterations in GABAAR expression and 
function (Treiman, 2001; Olsen et al., 1999; Jones-Davies and Macdonald, 
2003). GABAAR subunit expression is also altered in the hippocampi of animals 
with recurrent seizures (Kokaia et al., 1994) and TLE patients (Brooks-Kayal et 
al., 1998b; Loup et al., 2000). Mutations in GABAAR subunits have been found in 
number of human syndromes that cause seizures and epilepsy. Seizures are a 
symptom of Angelman's syndrome, in which there is a deletion on the 
chromosome region encoding the β3 subunit (DeLorey et al., 1998). Mutations in 
the γ2 subunit are linked to childhood absence epilepsy and febrile seizures 
(Bianchi et al., 2002) and a α1 subunit loss-of-function mutation lease to Juvenile 
Myoclonic Epilepsy (Cossette et al., 2002).  
Using the pilocarpine-induced rat model of SE and primary cultured 
hippocampal neuron system, studies in our laboratories have found that BDNF 
signaling controls the subunit composition of the type A receptor for GABA 
(Roberts et al., 2005). We further established that BDNF transcriptionally 
regulates differential expression of type A GABA receptor (GABAAR) subunits 
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genes (Gabrs) after SE through two signaling pathways. The product of this 
regulation is the downstream replacement of synaptic α1-containing GABARs 
with α4-containing GABARs that also contain the γ2 subunit, which enhances 
excitability of dentate granule cells (Brooks-Kayal et al., 2009; Roberts et al., 
2005; Lund et al., 2009).  
Epilepsy also alters the trafficking and localization of GABAARs in the 
hippocampus. In the dentate gyrus (DG), Increased endocytosis of synaptic 
GABAARs occurs from decreased phosphorylation of the β3 subunit, leading to 
increased association with the clathrin adaptor AP2 (Naylor et al., 2005; Goodkin 
et al., 2005; Terunuma et al., 2008). Aberrent sprouting of GABAergic neurons 
has also been reported in the dentate gyrus (Coulter, 2001), as well as increases 
in extrasynaptic expression of α4 and δ subunits (Fritschy et al., 1999; Brooks-
Kayal et al., 1998b; Schwarzer et al., 1997). Overall, these changes are thought 
to cause dysfunction in inhibitory signaling in the hippocampus of epileptics.  
C. Adult Neurogenesis  
1. Adult Neurogenesis and Maturation 
 Neurogenesis is the generation of newborn neurons and subsequent 
integration of these neurons into neuronal networks (Ming and Song, 2005; Balu 
and Lucki, 2009; Aimone et al., 2014). While neurogenesis happens most 
extensively during development, it also continues through adulthood, but is 
limited to three areas of the brain: the subgranular zone (SGZ), subventricular 
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zone (SVZ), and the olfactory neuroepithelia (Ming and Song, 2011). Neurons 
produced in the SGZ migrate short distance to the granule cell layer of the 
dentate gyrus (DG) of the hippocampus, becoming dentate granule cells (DGCs). 
About 6% of the granule cell layer is made of up adult-born neurons (Cameron 
and McKay, 2001), which integrate into hippocampal circuitry and acquire 
characteristics of mature DGCs (Ge et al., 2006; van Praag et al., 2002). These 
DGCs are very stable and may replace DGCs that were born during development 
(Dayer et al., 2003). SVZ neurons migrate through the rostral migratory system 
and become granule neurons and periglomerular neurons for the olfactory bulb 
(Lledo and Saghatelyan, 2005). The olfactory neuroepithelia produces excitatory 
sensory neurons whose axons project to the olfactory bulb. It is not known 
whether neurogenesis occurs in other adult mammalian brain areas, besides the 
SVZ and SGZ (Gould, 2007; Rakic, 2002).   
 Once in the DG, new neurons go through developmental stages both 
physiologically and morphologically (Esposito et al., 2005; Ge et al., 2006; 
Overstreet Wadiche et al., 2005; Zhao et al., 2006). Newborn granule cells 
initially depolarize in response to GABA because of high intracellular 
concentration of chloride ions, which is important given that knockdown of 
chloride ion channel NKCC1 causes a defect in neuronal maturation (Ge et al., 
2006). Around two to four weeks after neuronal birth, when dendritic spines have 
grown and respond to glutamate, the response to GABA switches from 
depolarization to hyperpolarization. During this time, new neurons have lower 
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thresholds for long-term potentiation (Ge et al., 2007; Schmidt-Hieber et al., 
2004) and do not show activity-dependent expression of immediate early genes 
(Jessberger and Kempermann, 2003), but experience during this time can affect 
the expression of activity-dependent immediate early genes at six weeks of age 
or older (Kee et al., 2007; Tashiro et al., 2007). After about four weeks, newborn 
neurons show a mature phenotype, yet still undergo changes in LTP amplitude 
and spine density (Ge et al., 2007; Toni et al., 2007; Zhao et al., 2006). When 
they have matured, granule cells receive similar glutamatergic and GABAergic 
inputs as existing neurons (Laplagne et al., 2006; Laplagne et al., 2007).  
Newborn neurons in the olfactory bulb also go through distinct stages of 
development (Lledo et al., 2006; Petreanu and Alvarez-Buylla, 2002), developing 
functional GABA receptors before glutamate receptors or dendritic spines (Lledo 
and Saghatelyan, 2005). Many newborn neurons die within 4 weeks and their 
survival is regulated by different mechanisms. Survival of one- to three-week-old 
newborn SGZ neurons is dependent on experience, such as spatial learning and 
enriched environment (Kee et al., 2007; Tashiro et al., 2007) and NMDA 
signaling is important at three weeks. Survival of newborn granule neurons in the 
olfactory bulb also depends on sensory input (Petreanu and Alvarez-Buylla, 
2002).  
2.  Regulation of Adult Neurogenesis 	
 Adult neurogenesis is regulated by physiological and pathological activity, 
such as, adult neural stem cell (NSC) or progenitor proliferation, progenitor cell 
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differentiation and fate determination, and the survival, maturation, and 
integration of newly born neurons. These cells may also be needed for brain 
functions involving the olfactory bulb and hippocampus, which is important for 
learning and memory. Adult NSCs within the nervous system are able to self 
renew and differentiate into any type of neural cells, including neurons, 
astrocytes, and oligodendrocytes (Gage, 2000). Neural progenitor describes any 
dividing cells with the capacity to differentiate. Within the SGZ, two types of 
progenitors have been identified based on morphology and expression of 
different markers. Type 1 hippocampal progenitors express nestin, glial fibrillary 
acidic protein (GFAP), and the Sry-related HMG box transcription factor, Sox2, 
and have radial processes that span the granule cell layer, branching out to the 
inner molecular layer (Fukuda et al., 2003; Garcia et al. 2004; Suh et al., 2007).  
While these cells express GFAP, they have a distinct morphology and function 
from astrocytes. Type 2 hippocampal progenitors do not express GFAP and have 
short processes. Studies in vivo show that type 2 Sox2-positive cells are able 
self-renew and a single Sox2-positive cell may give rise to a neuron and an 
astrocyte (Suh et al., 2007). This study also suggests that the type 1 and type 2 
cells have a reciprocal relationship.  
 The SVZ contains three types of precursor cells, type B GFAP-positive 
progenitors, type C transit amplifying cells, and type A migrating neuroblasts. 
Type B GFAP-positive neural progenitors are thought to be relatively quiescent, 
and do not respond to antimitotic treatment (Doetsch et al., 1999). Type C and A 
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cells are identified by bromodeoxyuridine (BrdU) and 3H-thymidine labeling and 
by the molecular markers, Dlx2, doublecortin (DCX) and polysialylated neural 
adhesion molecule (PSA-NCAM). The potential of SVZ progenitor cells is limited, 
however, because their fate is determined by positional information established 
in early CNS development (Merkle et al., 2007). 
 The microenvironment, or neurogenic niche, of the SGZ and SVZ can 
contribute to their neurogenic capacity. In the SGZ, adult hippocampal 
progenitors are close to a dense layer of granule cells, which contains both 
mature and newborn immature neurons, as well as astrocytes, oligodendrocytes, 
and other types of neurons. Hippocampal astrocytes are thought to play a role in 
SGZ neurogenesis by promoting neuronal differentiation and integration of adult 
hippocampal progenitor cells in vitro (Song et al., 2002). Wnt signaling is likely 
involved, since blocking Wnt signaling inhibits the neurogenic activity of 
astrocytes in vitro and SGZ neurogenesis in vivo (Lie et al., 2005). Adult 
neurogenesis declines with age in the SGZ and SVZ (Rossi et al., 2008), with 
aged animals showing decreases in both the population of progenitors and their 
ability to self-renew in the SVZ (Molofsky et al., 2006). Whether the number of 
neural progenitors in the SGZ also declines with aging in unknown, but voluntary 
exercise can restore neurogenesis in aged animals to a certain extent, 
suggesting extrinsic affects on these cells (van Praag et al., 2005). 
 Neurotransmission and growth factor signaling can also affect 
neurogenesis. In the DG, NMDA receptor-mediated activity is inversely 
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correlated with proliferation in the hippocampus and neuronal differentiation is 
increased in hippocampal progenitors in response to glutamate treatment (Jang 
et al., 2007). Whether adult hippocampal progenitors express functional NMDA 
receptors is still uncertain. The NR1 NMDA receptor subunit is not expressed in 
proliferating cells in vivo (Deisseroth et al., 2004; Nacher and McEwen, 2006). 
The inhibitory neurotransmitter GABA depolarizes type 2 progenitors in the adult 
hippocampus, causing calcium ion influx and increased expression of NeuroD, a 
neuronal differentiation factor, suggesting that GABAergic input promotes type-2 
hippocampal progenitor differentiation (Tozuka et al., 2005). Calcium ion channel 
antagonists and agonists decrease and increase neuronal differentiation in the 
adult hippocampus, respectively (Deisseroth et al., 2004).   
 Adult neurogenesis within the hippocampus is thought to be a key feature 
of adult brain plasticity (Sahay et al., 2011), which underlies cognitive processing 
and is fundamental for specific brain functions such as spatial learning, pattern 
discrimination, contextual memory and mood regulation (Clelland et al., 2009; 
Denny et al., 2014). Neurogenesis in the SGZ can be influenced genetics and 
environment (Kempermann and Gage, 2002; Olson et al., 2006). Exercise 
increases cell proliferation and environmental enrichment promotes survival in 
the SGZ (Kee et al., 2007; Tashiro et al., 2007). Aging and stress can negatively 
affect SGZ neurogenesis (Klempin and Kempermann, 2007; Mirescu and Gould, 
2006). Other factors, such as structural plasticity, neurotrophins, and hormone 
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levels may contribute to the environmental influence on learning and memory 
(Olson et al., 2006). 
3. BDNF and Neurogenesis 	
 Neurotrophic factors (NTFs), whose genes are responsive to neuronal 
activity, support neuronal survival and finely modulate network construction, from 
neuronal migration to experience-dependent refinement of local connections 
(Poo, 2001). During nervous system development, neuron survival depends on 
the secretion of NTFs from target cells (Huang and Reichardt, 2001). NTFs also 
mediate neuronal plasticity in the adult brain, via axonal and dendritic growth and 
remodeling, membrane receptor trafficking, neurotransmitter release, synapse 
formation and function (Lu et al., 2005).   
 Brain derived neurotrophic factor (BDNF) is an important mediator of 
neuronal plasticity, due to its abundance in brain regions relevant to plasticity and 
activity-dependent expression and secretion (Bramham and Messaoudi, 2005). 
Transcriptional regulation of the rat BDNF gene is complex and regulated by 
specific signaling pathways (Pruunsild et al., 2011). Nine distinct transcripts can 
be generated through alternative splicing of 5’ un-translated exons to a common 
3’ exon (IX), which encodes the BDNF protein (Aid et al., 2007). Each transcript 
has a different distribution and/or translation efficacy and may serve different 
functions, such as transcripts localized to dendrites may sustain local 
neurotrophin production, regulating synaptic structure and function (An et al., 
2008; Wu et al., 2011). Neurogenesis requires precise spatial and temporal 
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control, but can be modulated by internal and external stimuli, including BDNF. 
Several studies have shown that BDNF increases adult neurogenesis in many 
areas of the brain, including the striatum, septum, thalamus, hypothalamus, and 
hippocampus (Pancea et al., 2001; Lee et al., 2002; Sairanen et al., 2005; 
Scharfman et al., 2005; Gass and Riva, 2007; Bergami et al., 2008; Chan et al., 
2008; Li et al., 2008; Waterhouse et al., 2012). 
 BDNF is involved in mood regulation and, along with SGZ neurogenesis, 
can be regulated by stress and antidepressants (Duman and Monteggia, 2006). 
BDNF mimics antidepressants and increases neurogenesis when infused into the 
DG, and mice with impaired BDNF signaling do not have increased neurogenesis 
with antidepressant treatment. Exercise, dietary restriction, and enriched 
environment, are able to both induce BDNF expression and increase SGZ 
neurogenesis. Both BDNF heterozygous mice (BDNF+/−) and mice expressing a 
dominant negative form of the TrkB receptor show decreased survival of 
newborn cells. An enriched environment is unable to enhance the survival of 
newborn cells in BDNF+/− mice (Rossi et al., 2006), suggesting BDNF signaling 
may enhance the survival of newborn neurons.  
4. Aberrent Neurogenesis in Epilepsy 	
 Seizure activity has been shown to increase neurogenesis in both the 
SGZ and SVZ. Altered neurogenesis in the hippocampal causes a number of 
cellular abnormalities, such as, increased proliferation of neural progenitors, 
production of ectopic granule cells (EGCs), mossy fiber sprouting (MFS), dentate 
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granule cell (DGC) layer dispersion, neuronal hypertrophy and persistence of 
hilar basal dendrites on adult-generated granule neurons (Parent et al., 1997; 
Scharfman, 2002; Pun et al., 2012). Rats with pilocarpine-induced TLE have 
increased neurogenesis in the rostral SVZ, and more rapid migration of 
neuroblasts from the SVZ to the olfactory bulb, with some premature exiting of 
the migratory stream (Parent et al., 2002). SE also increases cell proliferation in 
the SGZ in both pilocarpine and kainic acid rat models (Parent et al., 1997; 
Jessberger et al., 2005) and persists for weeks after a latent period of several 
days (Parent et al., 1997; Gray and Sundstrom, 1998). Proliferation rates return 
to baseline around three to four weeks after SE induction (Parent et al., 1997). 
Chronic TLE results in decreased neurogenesis five months after SE induction 
(Hattiangady et al., 2004), which is also seen in children with frequent seizures, 
where decreased proliferating cells and immature neurons have been seen in the 
DG (Mathern et al., 2002). 
 MFS occurs when mossy fiber axons abnormally branch out of the dentate 
hilus and project onto the dendrites of granule cells of the inner molecular layer. 
Most of these connections are excitatory, resulting in hyperexcitable recurrent 
loops in the DG (Koyama and Ikegaya, 2004). Recent studies, however, point to 
a complexity in the role of adult hippocampal stem cells in epilepsy and suggest 
that more information is needed to better understand how they are differentiated 
in the diseased brain. This is especially important because genetic ablation of 
adult rat hippocampus neurogenesis prior to SE reduces the frequency of 
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spontaneous recurrent seizures but does not completely prevent seizures (Cho 
et al., 2015). There is also a decrease rather than increase in neurogenesis 
reported after kainite-induced hyperactivity due to the increased production of 
astrocytes rather than neurons from neural stem cell progenitors (Sierra et al., 
2015). 
5. Markers of Neurogenesis 	
 Kempermann and colleagues proposed a model of developmental 
milestones in adult neurogenesis identified by morphology, proliferative ability, 
and expression of markers (Kempermann et al., 2004). The division of a stem 
cell (type-1), which has radial glia and astrocytic properties (Seri et al., 2001), 
gives rise to three consecutive stages of putative transiently amplifying progenitor 
cells (type-2a, type-2b, type-3) differing in proliferative potential and increasing 
differention. These stages lead to exit from the cell cycle into a transient 
postmitotic stage, marked by a calretinin (CR)-expressing immature granule cell, 
which establishes network connections and is selected for long-term survival. 
The final stage results in a terminally differentiated, calbindin (CB)-expressing 
mature granule cell. Figure 1 summarizes these stages and indicates when these 
cellular markers can be identified (Knoth et al., 2010).   
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Figure 1: Markers of neurogenesis in the human hippocampus related to 
adult hippocampus neurogenesis in rodents  
(adapted from Knoth et al., 2010). 
D. BDNF Signaling  
1. ProBDNF and Mature BDNF 
Brain derived neurotrophic factor (BDNF) is a member of the neurotrophin 
family, which also contains nerve growth factor (NGF), neurotrophin-3 (NT-3), 
and NT-4. Nerve growth factor, BDNF, and NT-3 are all expressed in neurons of 
the mammalian brain, with the highest levels observed in the adult hippocampus 
(Ernfors et al., 1991). BDNF is made and secreted from neurons, microglia and 
astrocytes (Lindholm et al., 1992; Rudge et al., 1992; Coull et al.; 2005; Lu et al., 
2009a; Trang et al., 2011) and plays an essential role in brain development that 
is reflected in its regulation over cellular differentiation and survival; as well as 
key aspects of neuronal plasticity (Bibel and Barde, 2000; Korte et al., 1995; 
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Korte et al., 1996; Zigova et al., 1998). BDNF is widely expressed throughout the 
brain in a similar pattern to TrkB (Binder, 2007) with the highest mRNA and 
protein expression in the granule and pyramidal cells of the hippocampus (Bibel 
and Barde, 2000; Bengzon et al., 1993; Ernfors et al., 1990) consistent with a 
critical role in long-term potentiation (LTP), neuronal survival, and axonal growth 
(Minichiello et al., 1999; Xu et al., 2000). 
Neurotrophins arise from precursors called proneurotrophins about 30-35 
kDa in size, which are cleaved into mature proteins about 12-14 kDa in size 
(Seidah et al., 1996). Intracellular proneurotrophins are cleaved either 
intracellularly or extracellularly after being secreted, or can be secreted without 
subsequent cleavage. Mature BDNF (matBDNF; 14 kDa) is cleaved from 
proBDNF (35 kDa) both intracellularly, by furin and protein convertases (protein 
convertase 1 or PC1), and extracellularly by zinc-activated matrix 
metalloproteinases (MMP) MMP3 and MMP7 (Lee et al., 2001), or plasmin, 
which is converted from inactive plasminogen by tissue plasminogen activator 
(tPA) (Plow et al., 1995). Plasminogen and tPA are widely expressed in the CNS, 
with plasminogen being exclusively expressed in neurons, the extracellular 
space, and at the synaptic cleft (Tsirka et al., 1997). High frequency neuronal 
activity (Gualandris et al., 1996), causing secretion of tPA into the extracellular 
space from axon terminals (Krystosek and Seeds, 1981), suggesting that tPA is 
the main trigger for the tPA/plasmin/proneurotrophin cascade. 
		29	
Studies results vary as to whether proBDNF is secreted intact after being 
synthesized in the endoplasmic reticulum (Matsumoto et al., 2008; Barker, 
2009b; Yang et al., 2009; Waterhouse and Xu; 2009; Park and Poo, 2013) or 
whether it is first cleaved to matBDNF and secreted from dense core vesicles in 
an activity, Ca2+ dependent manner (Lessmann et al., 2003 and Trang et al., 
2009). In the rat CNS, proBDNF is expressed in many regions, including the 
spinal cord, substantia nigra, amygdala, hypothalamus, cerebellum, 
hippocampus and cortex of rats (Zhou et al., 2004). Proneurotrophins either 
signal by binding and activating p75 neurotrophin receptor (P75NTR) or be 
degraded extracellularly. Pro-domains show substantial sequence homology and 
conservation among vertebrates and play an important role in intracellular 
processing (Suter et al., 1991; Rattenholl et al., 2001) and intracellular trafficking 
and secretion  (Lu, 2003).   
An important single-nucleotide polymorphism (SNP) was discovered in the 
pro-domain of the human BDNF gene at nucleotide 196 (guanine to adenine), 
producing an amino acid substitution (valine to methionine) at codon 66 
(Val66Met, metBDNF). Humans with this allele have impaired hippocampus 
dependent episodic memory, low levels of hippocampal N-acetylaspartate (NAA), 
a measure of neuronal integrity and synaptic abundance, and abnormal 
hippocampal function (Egan et al., 2003; Hariri et al., 2003). Looking at cultured 
hippocampal neurons, studies found that overexpression of metBDNF caused 
impaired intracellular trafficking, especially in distal dendrites, failed synaptic 
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targeting of vesicles containing BDNF, and impaired activity-dependent BDNF 
secretion (Chen et al., 2004; Egan et al., 2003), most likely due to difficulty 
generating BDNF-containing secretory granules. Co-expression of wildtype 
BDNF (wtBDNF) with metBDNF alters intracellular trafficking and regulates 
secretion of wtBDNF, and metBDNF forms a heterodimer with wtBDNF (Chen et 
al., 2004).  
2. Neurotrophin Receptors 	
 The way in which BDNF mediates differential effects in neurons is by 
signaling through two distinct receptors: the tropomyosin related kinase (Trk) 
receptor B (TrkB) and the p75 neurotrophin receptor (P75NTR). The TrkB 
receptor is a member of the receptor tyrosine kinase family, which inclues TrkA, 
TrkB, and TrkC. Each Trk family member has a unique set of amino acids in their 
extracellular domain, allowing for more selective associations between Trk 
receptors and their ligands (Friedman and Greene, 1999; Pérez et al., 1995). 
Most importantly, different neurotrophins show selective activation of Trk 
receptors that is reflected in their binding affinity: with NGF preferentially binding 
to TrkA, BDNF and NT-4 to TrkB, and NT-3 to TrkC (Barbacid, 1994).   
 P75NTR is a cell surface glycoprotein and a member of the tumor 
necrosis factor (TNF)-related receptor family (Naismith and Sprang, 1998). First 
identified as a neurotrophin receptor based on molecular recognition by NGF, it is 
now clear that p75NTR binds all neurotrophins (Rodriguez-Tébar et al., 1990; 
Rodríguez-Tébar et al., 1992). ProBDNF has a higher affinity for p75NTR than 
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the mature form (matBDNF) that selectively activates TrkB (Teng at al., 2005). 
Both TrkB and p75NTR are implicated in neurodegeneration (Ginsberg et al., 
2006; Schindowski et al., 2008) and in the etiology of multiple neurological 
disorders (Chao et al., 2006), including temporal lobe epilepsy (TLE) 
(Kandratavicius et al, 2014b) and traumatic brain injury (TBI) (Rostami et al., 
2014).  P75NTR has an extracellular domain with tandem arrays of cysteine-rich 
(CR) domains, which are required for neurotrophin binding. P75NTR typically 
binds to soluble dimeric ligands as a coreceptor (Reviewed by Barker, 2004).  
P75NTR homodimers are able to regulate the activation of receptor signaling 
(Vilar et al., 2009). P75NTR forms a coreceptor with many other proteins to 
mediating different cellular responses. Binding with Sortilin induces cell death 
(Nykjaer et al., 2004; Teng et al., 2005), while interactions with Trk receptors can 
facilitate neurotrophin binding (Teng and Hempstead, 2004; Esposito et al., 
2001). The transmembrane (TM) domain contains two residues that are involved 
in dimerization, cysteine 257 and glycine 266 (Vilar et al., 2009). The intracellular 
domain (ICD) can initiate signaling without ligand binding and like other TNF 
receptors, contains a unique death domain and has been linked to apoptosis 
(Majdan et al., 1997). The metalloproteinase TNFα-converting enzyme (TACE or 
ADAM17) can cleave P75NTR to produce an extracellular domain and a 24-kDa 
carboxyl-terminal fragment (CTF) (Zampieri et al., 2005; Kenchappa et al., 2010). 
The CTF is further processed in the TM domain by γ-secretase to release the 19-
kDa ICD into the cytosol (Kenchappa et al., 2006; Kenchappa et al., 2010. The 
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mature form of p75NTR contains O-glycoside-linked oligosaccharides clustered 
in a serine/threonine-rich stalk domain adjacent to the TM domain (Johnson et 
al., 1986; Radeke et al., 1987), as well as an N-glycosylation site (Large et al., 
1989). The structure of P75NTR is illustrated in Figure 2. 
 
Figure 2: Structure of P75 neutrophin receptor 
  
3. BDNF in Epilepsy 	
 In the hippocampus, BDNF is able to rapidly modulate excitatory and 
inhibitory synaptic transmission. In cultured hippocampal neurons, two to three 
minutes of BDNF treatment causes an increase in spontaneous firing rates, 
increasing both the amplitude and frequency of excitatory postsynaptic currents 
(EPSCs) (Levine et al., 1995). BDNF also increases field excitatory postsynaptic 
potentials (EPSPs) at Schaffer collateral-CA1 pyramidal cell synapses in adult 
hippocampal slices (Kang and Schuman, 1995). BDNF treatment inhibits GABAA 
receptor-mediated evoked and spontaneous inhibitory postsynaptic currents 
(IPSCs), effectively increasing the neural excitability of CA1 pyramidal cells, an 
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effect blocked by the tyrosine kinase inhibitor k252a, suggesting TrkB receptor 
activity mediation (Tanaka et al., 1997). Using entorhino-hippocampal slices, 
Scharfman (Scharfman, 1997) demonstrated that granule cell layer stimulation 
after an hour of BDNF treatment increased amplitude of CA3 population spikes, 
and after two hours of BDNF treatment, causes multiple population spikes in 
CA3. These effects do not occur in the absence of BDNF, suggesting that 
upregulation of BDNF in epileptic brains may cause abnormal enhancement of 
excitability in CA3 pyramidal cells (Scharfman, 1997).   
 In the pilocarpine-induced rat model of epilepsy, Scharfman and 
colleagues (1999) found that in hippocampal slice preparations with sprouting 
and BDNF up-regulation, BDNF enhances the excitability of granule cells in the 
DG by TrkB activation, an effect confirmed by whole-cell patch clamp recordings 
from dentate granule cells in slices from human TLE patients (Zhu and Roper, 
2001). They also found that BDNF, when co-treated with GABAA receptor blocker 
picrotoxin, rapidly increased the frequency and amplitude of spontaneous EPSCs 
and lasted up to an hour after removing BDNF, as well as BDNF-induced 
increase in size of EPSCs evoked by perforant pathway stimulation. Zhu and 
Roper (2001) also found that BDNF does not effect spontaneous IPSCs in 
granule cells in the presence of the glutamate receptor antagonists CNQX and 
AP5, but it decreases the amplitude of perforant pathway evoked IPSCs.  
 Koyama and colleagues (Koyama et al., 2004) found, in cultured 
hippocampal slices that were treated with picrotoxin for 10 days, robust MF 
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sprouting, abnormal excitability of dentate granule cells, and up-regulation of 
BDNF in the MF pathway, similar to that observed in both epilepsy patients and 
rat models, and was blocked by K252a or an anti-BDNF antibody. MF sprouting 
occurs when a BDNF-including bead is placed on the dentate hilus, even without 
neural activity, suggesting that BDNF induces the branching out of hilar axonal 
shafts.  
 The valine 66 to methionine (Val66Met) mutation in BDNF, which prevents 
cleavage from proBDNF to matBDNF, has been associated with many diseases 
(Sonali et al., 2013; Borroni et al., 2012; Fehér et al., 2009; Yu et al., 2008; He et 
al., 2007), but its association with epilepsy is conflicting. Recent evidence 
supports an association between this Val66Met polymorphism and epilepsy, with 
studies showing Val66Met may be associated with seizure susceptibility in small 
ethnic populations (Sha’ra et al., 2015), and that the Met66 allele may be 
protective against TLE (Shen et al., 2016). 
E. JAK-STAT Signaling  
1. Cytokine-Induced JAK-STAT Signaling 
 Cellular signaling pathways involving Janus kinase (JAK) and the signal 
transducer and activator of transcription (STAT) are known as JAK-STAT 
signaling. This pathway mediates proliferation, differentiation, migration, 
apoptosis, and cell survival, depending on the signal, tissue, and cellular context. 
JAK-STAT signaling is also necessary for numerous developmental and 
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homeostatic processes, such as hematopoiesis, immune cell development, stem 
cell maintenance, organismal growth, and mammary gland development 
(Ghoreschi et al. 2009). Polypeptide ligands, such as hormones, growth factors, 
or cytokines, bind to a receptor and induce receptor subunit multimerization. The 
ligands erythropoietin and growth hormone bind to receptor homodimers while 
interferons and interleukins bind to receptor heteromultimers. Signal propagation 
occurs when the cytoplasmic domain of these receptor multimers associated with 
JAK tyrosine kinases. JAK is activated when ligand-mediated receptor 
multimerization brings two JAKs in close together, allowing trans-
phosphorylation. JAKs have distinct tandem kinase-homologous domains at the 
C-terminus: a non-catalytic regulatory domain and a second with tyrosine kinase 
activity. JAK subsequently phosphorylates STATs, latent transcription factors in 
the cytoplasm, at a conserved tyrosine residue on the C-terminus. 
Phopshorylated STATs then dimerize through a conserved SH2 domain and 
translocate to the nucleus via importin α-5 (or nucleoprotein interactor 1) and the 
Ran nuclear import pathway, where is binds to DNA and regulates transcription 
(Nicolas et al., 2013). STAT dimers recognize an eight to ten base pair (bp) 
inverted repeat DNA element with consensus sequence 5’-TT(N4-6)AA-3’. 
Binding affinity of STAT dimers for a target DNA sequence is determined by the 
nucleotide sequence (Ehret et al., 2001). Once bound to their target promoter, 
STAT dimers induce transcription by recruiting nuclear co-activators, which 
mediate chromatin modifications and communication with core promoters. In 
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some cases, however, STAT binding can cause transcriptional repression 
(Ramana et al., 2001; Gil et al., 2001; Ivanov et al., 2001).   
 Protein kinases, including several mitogen-activated protein kinases 
(MAPKs), can phosphorylate STATs, which allows other cellular signaling 
pathways to potentiate the STAT-activating stimulus (Decker and Kovarik, 2000). 
Additional serine phosphorylation sites or posttranslational modifications may 
also regulate attenuation of STAT activity (Mowen et al., 2000; Ahmed and 
Ivashkiv, 2000). The JAK-STAT pathway is negatively regulated through receptor 
internalization and degradation, by protein tyrosine phosphatases acting on the 
receptor-kinase complex in membranes (David et al., 1995; Myers et al., 2001; 
Irie-Sasaki et al., 2001) or dephosphorylation of activated STAT dimers in the 
nucleus and recycling of STAT monomers to the cytoplasm (David et al., 1993). 
Suppressor of cytokine signaling (SOCS) proteins, whose expression can be 
stimulated by cytokines that cause STAT activation, can directly bind to and 
inactivate JAKs (Krebs and Hilton, 2001). Protein inhibitors of activated STATs 
(PIAS) can bind to phosphorylated STAT dimers and prevent DNA recognition 
(Shuai, 2000). Deregulation of JAK-STAT signaling is associated with cancers, 
immune disorders and cardiovascular diseases. There are four different JAK 
tyrosine kinases (JAK1, JAK2, JAK3, and TYK) and seven different STAT 
transcription factors (STAT1, STAT2, STAT3a, STAT3b, STAT4, STAT5a, 
STAT5b, STAT6). 
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2. JAK-STAT Signaling in the Central Nervous System 	
 In the CNS, JAK-STAT signaling is associated with gene regulation during 
development, hormone release, inflammation or tumorigenesis (Nicolas et al., 
2013). While JAK-STAT expression in the CNS is lower than other regions, these 
proteins are expressed in many brain areas, including the cerebral cortex, 
hippocampus, hypothalamus and cerebellum. Expression of these proteins varies 
during development, with high levels during embryonic stages (particularly JAK2, 
JAK1, STAT1, STAT3, and STAT6), and gradually decreases in expression 
during growth to adulthood (De-Fraja et al., 1998).  
 The JAK-STAT pathway is able to regulate the proliferation of NSCs. The 
cytokine interleukin 15 (IL-15) is expressed in adult NSCs in the SVZ, and 
induces activation of STAT1, STAT3 and STAT5, while JAK inhibitors block 
proliferation (Bauer, 2009; Gómez-Nicola et al., 2011). Leptin, through activation 
of STAT3 and Akt, regulates neuroproliferation in the DG of adult mice both in 
vitro and in vivo (Garza et al., 2008). Interferon β (IFN-β), the primary treatment 
for multiple sclerosis, activates STATs, but studies have shown varied results: 
inhibition (Lum et al., 2009), no affect (Hirsch et al., 2009) or enhancement of 
NPC proliferation (Arscott et al., 2011). JAK2 and STAT3 are involved in 
hippocampal synaptic plasticity independently of gene regulation (Nicolas et al., 
2012).  
 Glial differentiation is mediated by JAK-STAT signaling. Activation of 
ciliary neurotrophic factor (CNTF) receptor in embryonic cortical precursor cells 
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activates JAK1, STAT1 and STAT3, causing differentiation into astrocytes (Bonni 
et al., 1997), an effect also caused by microglia-derived IL-6 and leukemia 
inhibitory factor (LIF) cytokines (Nakanishi et al., 2007), and prolactin via JAK2, 
STAT1 and STAT3 (Mangoura et al., 2000). Numerous studies have found that 
STAT3 is involved in glial differentiation (Nakaniski et al., 2007; Cao et al., 2010; 
He et al., 2005), and conditional knockdown of STAT3 in mice enhanced 
embryonic neurogenesis and inhibited astrogliogenesis (Cao et al., 2010). 
STAT3 activation is also needed for neurogenesis in adult dentate gyrus (Müller 
et al., 2009), a divergence that could be explained by the embryonic and adult 
NSCs (Chao et al., 2006). JAK-STAT inhibitory proteins SOCS2, 3 and 6, can 
negatively regulate neuronal differentiation and neurite outgrowth induced by 
growth hormone (GH) and insulin-like growth factor-1 (IGF-1) (Gupta et al., 2011; 
Turnley et al., 2002). SOCS2 is expressed in neurons, and SOCS2-/- mice show 
impaired neurogenesis, while overexpression of SOCS2 increases neuronal 
differentiation (Turnley et al., 2002). JAKs isoforms have different roles, with 
JAK1 involved in astrocyte differentiation (Bonni et al., 1997), JAK2 involved in 
NSC proliferation (Garza et al., 2008; Kim et al., 2010), and JAK3 involved in 
NPC differentiation (Kim et al., 2010). 
 JAK-STAT also plays a role in neuron survival, apoptosis, and synaptic 
plasticity. Apoptosis can be induced by activation of STAT1 and STAT3 with IFN-
β (Dedoni et al., 2010), or activation of STAT1 alone by IFN-γ (Mäkelä et al., 
2010). IL-9, a JAK-STAT activator of STAT1 and STAT3, however, can protect 
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neonatal neurons (Fontaine et al., 2008).  This is likely because STAT activation 
causes rapid caspase activation, and later transcription of non-apoptotic proteins 
(Schindler et al., 2007). GH-induced increases in AMPA and NMDA receptor-
mediated EPSPs are reduced by AG490, a JAK2 inhibitor (Mahmoud and 
Grover, 2006). Cytoplasmic polyadenylation element binding protein 1 (CPEB-1) 
knockout (KO) in mice causes impaired synaptic plasticity and reduced activation 
of JAK2 and STAT3 (Mahmoud and Grover, 2006). JAK inhibition blocks the 
induction of NMDA receptor-dependent long-term depression (LTD) in rat 
hippocampal slices and STAT3 is activated after NMDA receptor-dependent LTD 
(Nicolas et al., 2012; Hofman and Kirsch, 2012). 
 Evidence shows that JAK-STAT is involved in several brain pathologies, 
including brain tumors, inflammation, and neurodegeneration. Human brain 
tumors have high levels of STAT activation, which causes impaired tumor 
recognition by the immune system (Gu et al., 2008). Anti-inflammatory cytokines, 
such as interleukin 10 (IL-10), activate STAT3, while pro-inflammatory cytokines, 
such as IFN-γ, causes JAK2-dependent STAT1 phosphorylation (Regis et al., 
2008). JAK2 and STAT3 may also protect neurons from degeneration. 
Neurotoxicity of Aβ can be reduced through the activation of JAK2 and STAT3 by 
nicotinic Acetylcholine receptors (Buckingham et al., 2009) or humanin (Chiba et 
al., 2009).   
3. BDNF-Induced Activation of JAK/STAT Signaling  	
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Studies in our laboratory have found that BDNF induces an increase in α4 
subunit levels through TrkB activation of the mitogen activated protein kinase 
(MAPK) pathway, which regulates synthesis of the transcription factor early 
growth response factor 3 (Egr3) (Roberts et al., 2005). BDNF signaling 
decreases GABAAR α1 subunit synthesis, and is dependent upon a TrkB-
mediated activation of the JAK-STAT pathway (Hokenson et al., in review; Lund 
et al., 2008). BDNF-induced activation of JAK-STAT signaling eventually leads to 
STAT3-mediated synthesis of inducible adenosine 3’, 5’-monophosphate (cAMP) 
early repressor (ICER), which binds to Gabra1 and attenuates its transcription. 
Interestingly, ICER is a repressor of signaling mediated by the cAMP-response 
element binding protein (CREB), and mediates the activity of higher order 
processes that underlie learning and memory (Borlikova and Endo, 2009). How 
BDNF-signaling activates the JAK-STAT pathway to attenuate the synthesis of 
synaptic GABARs, as well as other essential CREB-mediated gene products, 
remains unknown and is the subject of this manuscript.  
F. Late SV40 Factor 
1. Background and Function 
The Late Simian Virus 40 promoter factor (LSF) was first identified as an 
activator of the Late Simian Virus 40 promoter (Kim et al., 1987; Huang et al., 
1990; Shirra et al., 1994) and is a transcriptional regulator ubiquitously expressed 
in mice and in all human cell lines, where it regulates cell cycle progression, cell 
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growth, and development (Hansen et al., 2009; Bruni et al., 2002; Powell et al., 
2000). It has been given other names based on independent discovery of its 
binding to DNA and transcriptional regulation, including leader binding protein-1c 
(LBP-1) or upstream region binding protein-1 (UBP-1), both on the HIV long 
terminal repeat (Jones et al., 1988; Wu et al., 1988; Yoo et al., 1994), CCAAT 
binding protein-2 (CP2), on the murine α-globin promoter (Barnhart et al., 1988; 
Kim et al., 1988; Lim et al., 1992), and serum amyloid A3 enhancer factor-1 
(SEF1), on the murine serum amyloid A3 promoter (Huang et al., 1994). LSF is a 
502 amino acid long protein (about 57 kDa) that is part of a small, conserved 
family of transcription factors that includes two subfamilies, LSF/CP2 and 
grainyhead (GRH) (Venkatesan et al., 2003; Wilanowski et al., 2002; Traylor-
Knowles et al., 2010). Genes encoding for LSF/GRH have been identified in both 
mammalian and non-mammalian species (Swendeman et al., 1994; Traylor-
Knowles et al., 2010). Mammals have three to four members of each family in 
each genome, while other species have one gene of each subfamily. 
The human LSF subfamily contains LSF (chromosome 12q13), LBP-1a/b 
(chromosome 3), and LBP-9 (chromosome 2), (Swendeman et al., 1994; 
Cunningham et al., 1995). LSF (Ramamurthy et al., 2001; Swendeman et al., 
1994) and LBP-1a/b (Ramamurthy et al., 2001) mRNAs are ubiquitously 
expressed in developing and adult mice, and in all human cell lines examined 
(Veljkovic and Hansen, 2004). Disruption of the LSF/CP2 gene in mice does not 
seem to cause any harm, which is likely a result of redundancy between LSF and 
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paralog LBP-1a/b (Ramamurthy et al., 2001), which is ubiquitously expressed 
and binds to the same DNA motifs and partner proteins as LSF (Zhou et al., 
2000; Tuckfield et al., 2002).  
There are a number of identified LSF splice variants. LSF-Internally 
Deleted (LSF-ID or LBP-1d) (Shirra et al., 1994; Uv et al., 1994; Yoon et al., 
1994), lacks part of the DNA interacting domain, amino acids 189 to 239, which 
prevents DNA binding (Shirra et al., 1994; Uv et al., 1994) and inhibits binding of 
full-length LSF in vitro (Yoon et al., 1994; Zhong et al., 1994), and can function 
as a mutant dominant-negative LSF when expressed in cells (Drouin et al., 2002; 
Yoon et al., 1994). Another common splice variant of the LBP-1a/b gene is an 
alternative LBP-1b isoform, which contains an insertion of 36 amino acids relative 
to LBP-1a (Huang et al., 2000; Yoon et al., 1994), following the DNA-interaction 
region, which is important for transcriptional activation and nuclear localization in 
erythroid cells (Kang et al., 2005; Kang et al., 2010). The third splice variant, 
LBP9/CRTR-1, is less widely expressed and thought to be in involved in 
pluripotent stem cell development (Pelton et al., 2002). LBP-9 contains a unique 
transcriptional repression region (Rodda et al., 2001) and can reverse LBP-1b-
mediated transcriptional activation (Huang and Miller, 2000). 
LSF is localized to the nucleus in every cell type examined (Drouin et al., 
2002; Zambrano et al., 1998; Veljkovic and Hansen, 2004) except for 
differentiated rat B103 neuroblastoma cells (Kashour et al., 2003), but lacks an 
obvious nuclear localization signal. LSF-ID is exogenously expressed in the 
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cytoplasm (Drouin et al., 2002; Zambrano et al., 1998) suggesting residues 189 
to 239 are important for nuclear localization (Veljkovic and Hansen, 2004). 
2. DNA Binding and Transcriptional Activity 	
GRH and LSF DNA-binding domains are highly conserved and they bind 
to similar DNA motifs.  LSF binds to a DNA motif of directly repeated half sites on 
consecutive turns of the DNA helix (Huang et al., 1990) with the consensus 
sequence CNRG N6 CNRG (Lim et al., 1993; Shirra, 1995). LSF binds to DNA as 
a homotetramer through its DNA binding domain (residues 67-260) (Shirra and 
Hansen, 1998; Murata et al., 1998), while GRH binds a similar single DNA motif 
(Venkatesan et al., 2003) as a dimer (Attardi and Tjian, 1993; Shirra and Hansen, 
1998). LSF is primarily a dimer in solution (Shirra and Hansen, 1998; Zhong et 
al., 1994), suggesting that LSF dimers must form a tetramer to recognize and 
bind DNA. Residues 133-383 are required for DNA binding (Shirra and Hansen, 
1998). The C-terminal region of LSF is responsible for oligomerization (residues 
266-403) with residues 280-501 responsible for homooligomerization (Uv et al., 
1994; Zhou et al., 2000).  A LSF-LSF interaction region is also present in the 
DNA-binding domain (residues 211–213, 235–237), which is likely involved in 
tetramerization (Shirra et al., 1994; Shirra, 1995). LSF and GRH are unable to 
oligomerize, while members of the same subfamily can interact with one another 
(Ting et al., 2003b; Uv et al., 1994; Wilanowski et al., 2002; Yoon et al., 1994). 
LSF can bind with other subfamily members, such as LBP-1a/b, to bind LSF 
recognition sites, or bind with different proteins to create novel DNA-binding 
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moieties. Mutations of the DNA binding domain have lead to the discovery of 
Q234L/K236E LSF (dnLSF), which is unable to bind DNA and oligomerizes with 
wild-type LSF (wtLSF), as well as other LSF subfamily proteins (Shirra et al., 
1994). This mutated LSF has been a helpful dominant-negative in many 
biological studies (Drouin et al., 2002; Kashour et al., 2003; Powell et al., 2000).   
LSF typically activates transcription in mammalian tissue culture cells 
(Bing et al., 1999; Bing et al., 2000; Casolaro et al., 2000; Lim et al., 1993; 
Murata et al., 1998; Powell et al., 2000; Yoon et al., 1994; Zheng et al., 2001), as 
does LBP-1a/b (Huang et al., 2000; Yoon et al., 1994), but it can also repress 
transcription. The transcriptional activation regions are amino acids 1 to 65 and 
164 to 277, which can each activate transcription on their own (Veljkovic and 
Hansen, 2004). LSF also interacts with TATA-binding protein (TBP) and 
transcription factor TFIIB (Veljkovic and Hansen, 2004), which are components of 
basal transcriptional machinery. LSF increases the rate of association of TFIIB 
with a DNA in vitro, and can increase the total number of transcription complexes 
(Sundseth et al., 1992). LSF represses transcription from the HIV LTR via steric 
hindrance, which prevents TBP access to TATA (Kato et al., 1991; Coull et al., 
2002), and transcriptional elongation (Parada et al., 1995), by forming a 
heteromeric complex with YY1 and histone deacetylase 1 (HDAC1) (Coull et al., 
2000; Romerio et al., 1997). Interleukin-2 (IL-2) promoter is the only published 
cellular promoter that LSF downregulates (Casolaro et al., 2000). LSF amino 
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acids 266 to 396 are necessary for transcriptional repression (Veljkovic and 
Hansen, 2004). 
LSF can be regulated at a number of steps, including dimerization, 
tetramerization, and DNA interaction (Whitmarsh and Davis, 2000). Signal 
transduction pathways also regulate LSF. Extracellular-signal-regulated kinase 
(Erk) rapidly enhances DNA-binding of LSF in primary human T cells (Pagon et 
al., 2003; Volker et al., 1997). Activation of class switching in primary murine 
splenic B cells decreases DNA-binding of LSF to heavy chain immunoglobulin 
class switch regions (Drouin et al., 2002). Jurkat cell induction via calcium 
ionophores increases DNA-binding to the interleukin-4 (IL-4) promoter (Casolaro 
et al., 2000). Interleukin 1 (IL-1) signaling-induced inflammation increases LSF-
mediated stimulation of a serum albumin promoter in liver cells (Bing et al., 
2000). 
3. Phosphorylation and Regulation of Cell Cycle 	
The cell cycle is the duplication of DNA and subsequent division into two 
genetically identical daughter cells, and requires DNA duplication (S, or 
synthesis, phase), chromosome segregation and cell divisions (M, or mitosis, 
phase). Gap phases are added into the cell cycle to allow time for growth, 
including G1 phase between M and S phase, and G2 between S phase and 
mitosis.  Eukaryotic cell cycle contains the four phases; G1, S, G2, and M, with 
phases G1, S, and G2 collectively called interphase. G0 is a special resting phase 
that cells may remain in for long periods of time, and proliferative conditions can 
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cause G0 cells to pass through a start (or restriction) point in late G1 and re-enter 
the cell cycle (Reviewed by Alberts et al., 2002). 
Studies have found that LSF regulates cell cycle progression and may be 
important for cell survival (Veljkovic and Hansen, 2004). The re-entry of cells 
from G0 to G1 phases requires activation of signal transduction pathways, 
including the Erk family of MAP kinases, which target many transcription factors 
(Johnson and Lapadat, 2002; Yang et al., 2003; Zhang and Liu, 2002). G1 cyclin-
dependent kinases are required for cells to pass through the restriction point, 
commit to proliferation, and enter S phase. Cyclin D/cdk4 and cyclin D/cdk6 
complexes target pRb, which activates adenovirus E2 promoter factor (E2F) 
transcription factors. Cyclin E/cdk2 targets transcription factors, including NPAT, 
which stimulates histone gene expression (Ma et al., 2000; Zhao et al., 2000).  
Both Erk and cdk2 phosphorylate LSF (Powell, 1999; Volker, 1998; Pagon 
et al., 2003; Saxena et al., 2009). The major phosphorylation site is serine 291 
(S291), which can be phosphorylated within minutes of mitogenic stimulation 
(Pagon et al., 2003; Volker, 1998; Volker et al., 1997). MEK inhibition prevents 
S291 phosphorylation, suggesting Erk phosphorylates S291 (Pagon et al., 2003). 
Cyclin/cdk2 complexes also specifically phosphorylate LSF (Fecko, 2001; Powell, 
1999; Pagon et al., 2003; Saxena et al., 2009). LSF targets the thymidylate 
synthase (TS) gene by binding to cell cycle regulatory regions in promoter and 
intron sequences, and upregulating TS mRNA levels at the G1/S transition, 
promoting cell cycle re-entry (Powell et al., 2000). Expression of dnLSF blocks 
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the G1/S induction of TS expression and causes mouse fibroblasts and human 
prostate cancer cells to undergo apoptosis during S phase (Veljkovic and 
Hansen, 2004), an effect reversed by addition of thymidine (Powell et al., 2000). 
Overexpression of the interacting protein Fe65, which inhibits transactivation of 
LSF, causes cells to arrest at the G1/S transition (Bruni et al., 2002), an effect 
that can also be blocked by thymidine treatment (Powell et al., 2000). Another 
site of phosphorylation by cyclin C/Cdk2, is serine 309 (S309), which occurs in 
mouse fibroblasts in early G1, one to two hours after mitogenic stimulation 
(Saxena et al., 2009). Phosphorylation at both S291 and S309 inhibits the 
transcriptional activity of LSF. In late G1, dephosphorylation occurs at both sites, 
causing LSF activation and TS induction, suggesting that early G1 
phosphorylation inhibits LSF and prevents premature induction of LSF genes 
(Saxena et al., 2009).   
 
Figure 3: Structure and domains of LSF 
4. Role of LSF in Disease 	
 LSF has been implicated in a number of diseases. LSF regulates gene 
expression of human immunodeficiency virus (HIV) through three half-site motifs 
in the HIV long terminal repeat (LTR), causing transcriptional repression (Coull et 
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al., 2000; Coull et al., 2002; He and Margolis, 2002; Jones et al., 1988; Kato et 
al., 1991; Romerio et al., 1997). LSF has also been identified as an oncogene in 
hepatocellular carcinoma (HCC), promoting tumorigenesis and upregulating 
osteopontin (OPN), a gene that regulates tumor progression (Yoo et al., 2010).  
Treatment with factor quinolinone inhibitor 1 (FQI1), a small molecule inhibitor of 
LSF DNA-binding activity, reduces tumor growth and cytotoxicity (Grant et al., 
2012). 
 LSF has been linked to Alzheimer’s disease (AD) through a number of 
findings. Amyloid precursor protein (APP) is a transmembrane protein (Coulson 
et al., 2000) that is protealytically cleaved near the membrane (Hardy and 
Selkoe, 2002; Steiner and Haass, 2000) by either α and β secretase, which 
releases the extracellular domain. The carboxy-terminal (C-terminal) is 
subsequently cleaved by γ secretase within the membrane to produce APP 
intracellular C-terminal domain (AICD), which is released into the cell. The N-
terminal fragment of this product is secreted, and when first cleaved by β 
secretase, the peptide product is amyloid beta (Aβ). Aβ is correlated with plaque 
formation in the AD brain, while AICD may enhance apoptosis (Kögel et al., 
2012; Kim et al., 2003; Passer et al., 2000). Notch, like APP, can be cleaved by α 
and γ secretase and the Notch intracellular C-terminal fragment (NICD) 
translocates to the nucleus to mediate transcription. AICD localizes to the 
cytoplasm and nucleus (Cupers et al., 2001; Gao and Pimplikar, 2001; Kimberly 
et al., 2001) and interacts with a number of intracellular adaptor proteins (Neve et 
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al., 2000; Russo et al., 1998), including Fe65, which is expressed in the brain 
and shuttles between the cytoplasm and nucleus. Fe65 expression promotes 
nuclear localization of AICD (Kim et al., 2003; Kimberly et al., 2001). Fe65 can 
interact with a histone acetyltransferase Tip60, leading to a ternary 
AICD/Fe65/Tip60 complex (Cao and Südhof, 2001) or Fe65 can interact with 
LSF (Zambrano et al., 1998) and form a nuclear ternary AICD/Fe65/LSF complex 
(Kim et al., 2003). Exogenous overexpression of Fe65 causes increased nuclear 
localization and repression of LSF activation of the TS promoter (Bruni et al., 
2002). These findings suggest that LSF transactivation may be inhibited or 
activated by its association with Fe65/AICD. These complexes may compete for 
formation, given that Tip60 and LSF interact with the same domain of Fe65 (Cao 
and Südhof, 2001; Zambrano et al., 1998). Overexpression of APP protects 
neurons from apoptosis and in APP-lacking rat neuroblastoma B103 cells, 
expression of wild-type LSF enhanced protection from apoptosis, while dnLSF 
expression increased apoptosis, suggesting that LSF in involved in APP-
mediated cell survival (Kashour et al., 2003). In epidemiological studies, a 
polymorphism in the 3' untranslated region of the LSF gene has been linked to 
AD, with the A allele (compared to the G allele) being correlated with protection 
against AD (Lambert et al., 2000; Taylor et al., 2001; Luedecking-Zimmer et al., 
2003; Lendon and Craddock, 2001) while another study found that A allele was 
associated with an increased risk of early onset AD (Panza et al., 2004). 
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G. Major Hypothesis and Specific Aims of Thesis 	
Extensive studies have resulted in two predominant theories of 
epileptogenesis: The altered expression of γ-aminobutyric acid (GABA) receptor 
subunits, causing a shift from α1-containing GABARs to rapidly desensitizing α4-
containing GABARs at the inhibitory synapse; and abherrent neurogenesis, 
mainly in the hippocampus, resulting in increased excitability. The detailed 
regulation of these mechanisms still requires further study and could provide 
more therapeutic targets and help to develop new therapies. The major 
hypothesis of our studies is that BDNF signaling mediates a change in inhibitory 
neurotransmission by activating JAK/STAT and MAPK pathways whose 
downstream targets are critical determinants of epileptogenesis. Therapies 
aimed at regulating specific elements of these pathways may be effective in the 
treatment of a large number of cases of intractable epilepsy, for which no current 
therapies are effective. 
Our studies are focused on understanding TLE, the most common from of 
refractory epilepsy. While studies have uncovered many underlying mechanisms 
of this disorder, including increased BDNF signaling through TrkB and P75NTR 
(Takahashi et al., 1999), the complexities of these pathways have yet to be 
elucidated. We previously demonstrated (Lund et al., 2008.) that recombinant 
matBDNF increases pSTAT3 levels, which induces ICER, a potent inhibitor of 
genes containing cAMP response elements (CRE sites). We also found that 
STAT-dependent synthesis of ICER, in response to matBDNF, downregulates 
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the number of α1 containing synaptic GABARs. We now further report that both 
TrkB and p75NTR are required for BDNF-induced JAK-STAT signaling in 
neurons: TrkB at the membrane and p75NTR as part of an intracellular JAK2 
signalsome ((i)p75NTRJ2). An essential role for rapid TrkB activation (within 15 
minutes) as a requirement for JAK/STAT pathway signaling in neurons is 
discussed in light of biochemical findings that suggest BDNF induces the 
formation of p75NTR oligomers that include JAK2. Taken together, these recent 
findings suggest the existence of a new pathway in synaptic plasticity and the 
brain’s response to injury. 
The neuronal cell cycle is unique because a majority of adult neurons 
have long been thought to be post-mitotic or quiescent. The expression of cell 
cycle regulators, including cyclin D1, Cdk4, Rb proteins, E2Fs, and CKI, are 
detected in the adult brain at both a transcriptional and translational level (Koeller 
et al., 2008; Müller et al., 2010; Okano et al., 1993; Schmetsdorf et al., 2007; 
Ting et al., 2014; Cunningham et al., 2002). The role of these cell cycle 
regulators in neurons has been attributed to neuronal maturation, migration, and 
synaptic plasticity (Frank and Tsai, 2009; Lim and Kaldis, 2013). Some neuronal 
cell types, including sympathetic and cortical neurons, may upregulate cell cycle 
makers and try to re-enter the cell cycle in response to an acute insult, such as 
neurotrophic factor deprivation, activity withdrawal, DNA damage, oxidative 
stress, and excitotoxicity, only to die at the G1/S checkpoint. This is a process 
known as “abortive cell cycle re-entry” (Becker and Bonni, 2004; Liu and Greene, 
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2001). Because the cell cycle regulator LSF is uniquely poised to regulate 
movement of cells through the G1/S transition and has been previously identified 
as a candidate gene in Alzheimer’s disease (Taylor et al., 2001), we 
hypothesized that it might also be a target for BDNF regulation in neurons with 
the potential of regulating cell fate in response to SE. 
We show that BDNF induces phosphorylation specifically at serine 291 in 
primary neuronal cultures and the hippocampus of rats in the pilocarpine model 
of TLE. Actively dividing neurons do not express p291 LSF, however, p291 LSF 
is expressed in neurons throughout the stages of adult neurogenesis and 
persists in mature neurons, as identified using markers of cell differentiation. 
Phosphorylation of LSF at p291 is highest in brain tissue where adult 
neurogenesis is most active, such as the olfactory bulb and hippocampus, when 
compared to cortex.  Whether LSF has a role in the determination of neuronal 
fate requires further study, however, association with both BDNF signaling and 
SE suggests that it has a novel role in the brain and may provide a unique target 
for future therapeutic intervention. 
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II: MATERIALS AND METHODS 
1. Primary neuronal cell culture 	
 Primary cortical and hippocampal neuronal cultures were prepared from 
embryonic day 18 (E18) Sprague-Dawley rats (Charles River Laboratories, MA).  
Pregnant female rats were euthanized (95% CO2/5% O2) and the embryos were 
removed. In ice-cold CMF solution [35mg/mL Bovine serum albumin, Ca+/Mg+ 
free Hank’s Buffered Saline Solution (HBSS), 1mM sodium pyruvate, 4.2mM 
sodium bicarbonate, 20mM hydroxyethyl piperazineethanesulfonic acid 
(HEPES)], the hippocampus and cortex were dissected from the embryonic 
brains. Cortical tissue was trypsinized in 0.05% trypsin/EDTA (10 minutes, 37°C, 
5% CO2) and the reaction was quenched with pre-warmed (37°C, 5% CO2) 
neuron plating medium [Neurobasal® Medium (NBM, GIBCO Life Technologies 
#21103-049), 10% fetal bovine serum (FBS), 100U/mL L-glutamine, 100U/mL 
peniclillin/streptomyocin]. Cells were pelleted, washed twice with CMF, and 
triturated in 1mL of neuron plating medium before resuspending in more media 
(10 mL total). Cells were counted using a hemocytometer and plated on poly-L-
lysine-coated plates (Nunc) at a density of 0.5 million cells per 1mL. 
Hippocampal tissue was triturated in 1mL of CMF, pelleted, and resuspended in 
neurobasal plating medium (5mL) before counting and plating. Plated cells were 
incubated (one hour, 37°C, 5% CO2) before media was replaced with neuron 
feeding media (NBM, 2% B27 supplement, 100U/mL L-glutamine, 100U/mL 
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peniclillin/streptomyocin). Neuron cell cultures were incubated (37°C, 5% CO2) 
until use.  
2.  Human embryonic kidney cell line  	
 Human embryonic kidney cell lines (HEK 293; ATCC #CRL-1573) were 
started by thawing frozen cells in a water bath (37°C, 2 minutes) and transferred 
to a vial with 9mL pre-warmed HEK feeding media [Dulbecco's Modified Eagle 
Medium (DMEM; GIBCO Life Technologies #11965-092), 10% FBS, 1X MEM 
non-essential amino acids (GIBCO Life Technologies #11140-050)]. Cells were 
centrifuged (125XG, 5-7 minutes), the pellet was resuspended in HEK feeding 
media, plated on a 75cm2 flask, and incubated (37°C, 5% CO2) to allow cell 
growth.  Cells were maintained until 90-100% confluency before splitting.  To split 
HEK cells, cells were washed once with 1X PBS, trypsinized with 0.05% 
trypsin/EDTA (5 min, 37°C, 5% CO2) to remove cells, quenched with HEK 
feeding media, and centrifuged (2500RPM, 5 minutes) to pellet cells. Cells were 
resuspended in 10 mL HEK feeding media and triturated well before plating in a 
new 75cm2 flask flask at a 1/10 or 1/20 dilution of the cell suspension. HEK cell 
plating for experiments differed based on the type of experiment. 
3.  Adult rat brain dissection 	
 For adult brain tissue analysis, brains were removed from pregnant adult 
female Sprague-Dawley rats used for embryo dissection. Brains were kept on ice 
while the prefontal cortex, hippocampus, and olfactory bulb were bilaterally 
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dissected. Tissue was homogenized in Radioimmunoprecipitation assay (RIPA) 
lysis buffer [1X RIPA (Millipore 20-188), 10mM Tris pH 7.4, 1% NP40, 150mM 
NaCl, 0.1% SDS, 1X protease inhibitor cocktail, 1X phosphatase inhibitor, 1mM 
phenylmethyl-sulfonyl fluoride (PMSF), 1mM sodium orthovanadate, 1mM 
sodium fluoride] using an electronic pestle and passed through a fine tipped 
syringe for further homogenization. Samples were incubated (on ice, 5 minutes), 
centrifuged (high speed, 10 minutes), and the supernatant was saved for total 
protein analysis. 
4. Recombinant BDNF and Drug Treatments  	
 Neuron treatments were done on 7 or 8 days in vitro (div) and in a 
controlled environment (37°C, 5% CO2). Recombinant human brain derived 
neurotrophic factor (matBDNF; Millipore GF029), mutant (cleavage resistant) 
human proBDNF (Alomone; B-256), were treated alongside vehicle (water) 
control samples. Mutant proBDNF contains a single-nucleotide polymorphism 
(SNP), valine 66 to methionine, in the pro-domain that impairs intracellular 
trafficking and regulated secretion of BDNF in primary cortical neurons (Chen et 
al., 2004). Time and concentration of treatment varied based on protein or mRNA 
of interest. For drug pre-treatments, TrkB inhibitor K252A (Calbiochem 420298; 
100nM), JAK/STAT inhibitor Ruxolitinib (Selleckchem S1378; 100nM), MEK 
inhibitor U0126 (Calbiochem 662005; 20µM), JAK/STAT inhibitor Pyridone 6 
(Calbiochem 420099; 500nM), or vehicle (dimethyl sulfoxide; DMSO), were 
added to cells for one hour before treatment. For treatment with potassium 
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chloride (KCl, Boston BioProducts MT-250), neurons were treated with either KCl 
(20mM) or vehicle (water) for 2 hours.  
5. Transfection  	
Calcium phosphate  
 Calcium phosphate transfection was used for HEK 293 cells and in some 
neuron culture experiments. Transfection was done 6 to 7 days in vitro (div) for 
neurons. Conditioned media was removed from cells, filtered (0.2µm), and saved 
(37°C, 5% CO2). Cells were washed once with pre-warmed DMEM (GIBCO Life 
Technologies #11960-044 for neurons, #11965-092 for HEK), and fresh DMEM 
was added to each well. Plates were incubated (37°C, 5% CO2; 15 minutes for 
neurons, 1 hour for HEK) until DNA was added. Amount of plasmid DNA used 
was dependent on the number of cells being transfected (8ug DNA for 1 million 
cells, 20ug DNA for 5 million cells). Plasmid DNA was diluted in water before 
adding calcium chloride (2.5M CaCl2), and transferred drop-wise with constant 
mixing into 2X HEPES-buffered saline (HeBS; 274mM NaCl, 10mM KCl, 1.4mM 
Na2HPO4.7H2O, 15mM dextrose, 42mM HEPES). DNA solution was incubated 
(20 minutes, dark, room temperature) before adding to cells and incubating 
(37°C, 5% CO2; 45 minutes for neurons, 3 hours for HEK). Olates were washed 
twice with DMEM, and filtered conditioned media was added. 
Electroporation 
 Electroporation transfection of neurons was done on div 0. After 
determining the neuron count and concentration, the volume of cells needed (2 
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million cells per 30mm dish) were removed and centrifuged (80xg, 5 minutes, 
room temperature) to obtain a pellet. Two million cells were resuspended in 
100ul Rat Neuron Nucleofector® Solution (with added supplement) from the 
Amaxa® Rat Neuron Nucleofector® Kit (Lonza VPG-1003). DNA (3ug per 2 
million cells) was added to the cell solution, tranferred into a cuvette, placed in 
the Nucleofector® II, and program C-009 was applied. DMEM (500ul, 10% FBS) 
was added to the cuvette with a pipette and the entire volume was transferred to 
pre-warmed plates with neurobasal feeding media. After incubating (37°C, 5% 
CO2; 2 hours), media was replaced with fresh neurobasal feeding media. 
NeuroMag Magnetofection™ 
 NeuroMag transfection was done on primary neuron cultures at 6 or 7 div, 
using a NeuroMag Magnetofection™ kit (Oz Biosciences #KC30800). Plasmid 
DNA was diluted in NBM and added to NeuroMag Transfection Reagent. The 
DNA solution was incubated (20 minutes, room temperature) before being added 
to neuron dishes and incubated on a magnetic plate (20 minutes, room 
temperature) provided in the kit. Cells were removed from the plate and 
incubated (37°C, 5% CO2) for 24 hours before assaying. 
6. P75NTR constructs and mutations 	
 Phillip Barker (McGill) generously provided us with human p75NTR:Flag 
cDNA in a pcDNA 3.0 vector. To make human transmembrane mutants 
comparable to previously studied rat p75NTR constructs (Vilar et al., 2009), we 
did a BLAST alignment of rat and human p75NTR and determined that rat 
		58	
cysteine 257 aligned to human cysteine 256, and rat glycine 266 aligned to 
human glycine 265. Two mutants were generated (Mutagenix) from the human 
p75NTR:Flag construct: cysteine 256 to alanine, p75NTR(C256A):Flag; and 
glycine 265 to isoleucine, p75NTR(G265I):Flag.    
7. RNA extraction and Real-Time PCR 	
 To generate a standard curve for ICER mRNA expression, neurons were 
treated with Forskolin (4 hours, 20uM). For all RNA extractions, an RNeasy Micro 
Kit (Qiagen #217084) was used. After treating, cells were washed with ice-cold 
1X PBS and buffer RLT (containin 2-mercaptoethanol) was added to each well. 
Cells were scraped, collected, vortexed (1 minute, high) and passed through a 
fine-tipped needle (20 gauge) 10-15 times. Ethanol (70%) was added to the 
samples and transferred to a microcolumn. DNase I was added (15 minutes) and 
RNA was eluted in 14ul RNase-free water. Nanodrop was used to measure RNA 
levels. Taqman one-step RT-PCR master mix (Applied Biosystems 4309169) 
was used for RT-PCR reactions. RT-PCR reactions were performed using the 
ABI PRISM 7900HT (Applied Biosystems), with a cycle of 50°C for 30 minutes, 1 
cycle of 95°C for 10 minutes, and then 50 cycles of 95°C for 15 seconds and 
60°C for 1 minute. ICER mRNA was detected using Taqman Rat Crem kit (Life 
Technologies 4331182). Primers and probes for cyclophilin (cyc) and GABAAR 
α1 were designed previously in our laboratory using primer express software (PE 
Biosystem, see table below). All mRNA was normalized to rat cyclophilin (cyc). 
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Gene 
 
 
Sequence 
 
Cyclophilin 
 
Forward: 5’-TGCAGACATGGTCAACCCC 
Reverse: 5’- CCCAAGGGCTCGCCA 
Taqman Probe:  5’-CCGTGTTCTTCGACATCACGGCTG 
 
 
GABAAR α1 
 
Forward: 5’-CCCCGGCTTGGCAACTA 
Reverse: 5’-CGGTTTTGTCTCAGGCTTGAC 
Taqman Probe: 5’-TGCTAAAAGTGCGACCATAGAACCGAAGA 
 
 
8. Preparation of Whole Cell Protein Extracts 	
 Cells were washed once, scraped, and collected from plates in ice-cold 
PBS-EDTA (1X, pH 7.4) containing protease inhibitor (1X, Roche 
#11697498001), phosphatase inhibitor (1X, Roche #04906837001) and 1mM 
PMSF. Samples were centrifuged (1500 RPM, 5 minutes) to pellet cells, and 
resuspended in RIPA lysis buffer. The resuspended cells were vortexed (10 
seconds, high) and incubated on ice (20 minutes). Samples were centrifuged 
again (13500 RPM, 10 minutes) and the supernatant containing total protein was 
removed and saved. Total protein concentration was measured via Bradford 
Assay (Bio-Rad Laboratories #500-0006). For storage, protein extracts were kept 
at -80°C. 
9. Western Blot Analysis 	
Total protein samples containing 30ug protein (unless otherwise noted), 
non-reducing lane maker sample buffer (1X, Thermo Scientific #39001), and 
Dithiothreitol (DTT, 100mM) were boiled (95°C, 5 minutes), loaded and run on 
Novex® 10% tris-glycine gels (Invitrogen #EC6078). For non-denaturing 
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conditions, samples were made without DTT. Gels weretransferred to 
nitrocellulose membranes, and membranes were blocked at room temperature in 
5% milk/tris-buffered saline with 0.05% tween-20 (TBS-T) for one hour. 
Membranes were incubated in primary antibodies overnight at 4°C. Polyclonal 
rabbit antibodies were raised against phospho-TrkB Tyr490 (Cell Signaling 
Technology 9141; 1:1000), phospho-STAT3 Tyr705 (Cell Signaling Techonology 
9131; 1:2000), p75ICD (Phil Barker Lab; 1:500), or GFP (Sigma Aldrich G1544; 
1:1000). Monoclonal rabbit antibodies were raised against phospho-JAK2 
Tyr1007/1008 (Cell Signaling Technology 3776; 1:1000), JAK2 (Cell Signaling 
Technology 3230; 1:1000), STAT3 (Cell Signaling Technology 4904; 1:2000), or 
p75NTR (Novus Biologicals NB110-58000; 1:1000).  Primary mouse monoclonal 
antibodies were raised against TrkB (BD Biosciences 610101; 1:1000), Sortilin 
(BD Biosciences 612100 1:1000), and β actin (Sigma Aldrich A5441; 1:5000). Dr. 
Ulla Hansen (Boston University) generously supplied the antibodies we used 
against LSF. Polyclonal rabbit antibodies were raised against phospho-LSF S291 
(1:3000), phospho-LSF S309 (1:300), and total LSF (1:500). Primary mouse 
monoclonal antibodies were raised against β actin (Sigma Aldrich A5441; 
1:5000). Primary antibodies were diluted in either 5% milk TBS-T or 5% bovine 
serum albumin (BSA)/TBS-T (including phospho-specific antibodies). Blots were 
incubated in the proper secondary antibodies (in 5% milk/TBS-T) for 1 hour at 
room temperature. Secondary antibody goat anti-rabbit IgG-HRP (Santa Cruz 
Biotechnology 2004; 1:2000) was used against rabbit primary antibodies. 
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Secondary antibody peroxidase horse anti-mouse IgG (Vector Laboratories PI-
2000; 1:2000) was used against mouse primary antibodies. Protein bands were 
visualized with ECL chemiluminescence (GE Healthcare #RPN2106). 
ImageQuant software was used to conduct densitometry analysis and protein 
bands were normalized to loading control β-actin. For phospho-specific 
antibodies, protein was normalized to total protein bands. 
10. siRNA knockdown  	
 Ambion was used to design and synthesize siRNAs for TrkB and p75NTR. 
Negative control siRNA was also obtained from Ambion (#AM4620).  The 
followed sequences were used: 
 
Gene 
 
Sequence 
 
 
TrkB(Ntrk2)-1 
 
Sense 5’-CAACCAUCACAUUUCUCG 
Antisense 5’-UCGAGAAAUGUGAUGGUUG 
 
 
TrkB(Ntrk2)-2 
 
Sense 5’-CAAGGACUUUCAUCGCGAA 
Antisense 5’-UUCGCGAUGAAAGUCCUUG 
 
 
p75NTR(Ngfr)-1 
 
Sense 5’-GGCUGAUGCUGAAUGCGAA 
Antisense 5’-UUCGCAUUCAGCAUCAGCC 
 
 
p75NTR(Ngfr)-2 
 
Sense 5’-GCCUGGACAAUGUUACAUU 
Antisense 5’-AAUGUAACAUUGUCCAGGC 
 
 
For p75NTR siRNA transfection, RNAifect transfection reagent (Qiagen) was 
used on primary neuron cultures 5 div. siRNA (1ug per well) were dileted in 
100uL of buffer EC-R, and complex formation was initiated with the addition of 
RNAiFect transfection reagent (12uL). Complex solution was incubated (15 min, 
room temperature), and added to the cells and incubated for 24 hours ((37°C, 5% 
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CO2).  The conditioned media was replaced with NBM and siRNA transfection 
was repeated and incubated overnight. Neurons were then treated with 
matBDNF (50ng/mL) for 4 hours and collected for analysis. For TrkB siRNA 
knockdown studies, the neurons were transfected via electroporation, using the 
Amaxa Rat Neuron Nucleofector kit (Lonza, #VPG-1003), as described in 
Methods section 5. 
11. Co-Immunoprecipitation 	
 HEK cells were co-transfected via calcium phosphate precipitation of 
p75NTR-Flag or p75NTR-flag mutants C256A or G265I in combination with 
JAK2:eGFP (gift of Dr. Ross Levine, Mount Sinai School of Medicine). For 
inhibitor studies, ruxolitinib (100nM) was added right after transfection. For all 
transfected cells, protein was collected 24 hours after transfection. Protein was 
extracted using a Universal Magnetic Co-IP kit (Active Motif 54002). Cells were 
washed and scraped in 1X PBS (with protease inhibitor cocktail, phosphatase 
inhibitor, and deacetylase inhibitor), centrifuged (1500 RPM, 5 minutes) to pellet 
cells, and resuspended in whole cell lysis buffer (Active Motif). The cell 
suspension was vortexed (10 seconds, high) and incubated on ice (30 minutes). 
Samples were centrifuged again (13500 RPM, 10 minutes) and the supernatant 
containing total protein was removed and saved. Total protein concentration was 
measured via Bradford Assay. For immunoprecipitation, total protein (500ug) was 
incubated overnight at 4°C on a rotating platform with a rat Flag primary antibody 
(anti-Flag) (Sigma Aldrich 7425; 6.4ug) or normal rabbit IgG (Santa Cruz 
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Biotechnology sc-2027) control. Protein G magnetic beads were added and 
incubated for 1 hour at 4°C on a rotating platform. Inputs were made from either 
collected flow through from first wash or original protein. Magnetic beads were 
washed three times before eluting in SDS-Buffer (with DTT). Samples were 
analyzed via Western blot and probed for presence of GFP. A Veriblot for IP 
secondary antibody (abcam #ab131366) was used for IP immunoblots. 
 For endogenous co-immunoprecipitation (Co-IP), protein was extracted 
from treated primary neuronal cultures. Protein was collected using RIPA lysis 
buffer.  
12. Immunocytochemistry  	
Primary cortical and hippocampal neurons were fixed for 10 minutes in 
fixing solution [4% paraformaldehyde (Electron Microscopy Sciences #15710-S), 
25mM Hepes, 150mM NaCl, 1mM CaCl2, 1mM MgCl2] at room temperature, and 
washed and permeabilized in 1% BSA/0.1% Triton-X/1X PBS for 20 minutes.  
Plates were incubated overnight at 4°C with primary antibodies to either p291 
LSF, p309 LSF, or total LSF and either NeuN (1:250; mouse polyclonal, 
Chemicon), the polysialylated embryonic form of the neural cell adhesion 
molecule (PSA-NCAM; 1:200; Millipore #MAB5324), Nestin (1:200; abcam 
#ab6142), MAP2 (1:750; abcam #ab11267), or p75NTR (1:500, Promega 
#G323A) in 1% BSA/1X PBS. The following secondary antibodies were used: 
goat anti-rabbit Alexa Fluor 488 (Life Technologies A-11008) and/or anti-mouse 
IgG Texas Red (Vector TI-2000) in 1% BSA/1X PBS, for two hours at room 
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temperature in the dark. For all immunocytochemistry, cells were mounted with 
ProLong Gold Antifade Mountant with DAPI (Thermo Fisher P36941) for 
microscopy. Cells were visualized on a Nikon Eclipse TE2000-S microscope at 
10X or 20X magnification. Imaging was done with Nikon Elements software and 
analyzed using ImageJ software.  
For colocalization studies, primary cortical neurons were transfected via 
calcium phosphate precipitation using JAK2:eGFP. Twenty-four hours after 
transfection, cells were fixed in fixing solution (10 minutes), washed and 
permeabilized in 5% BSA/0.1% Triton-X/1X PBS (20 minutes). Plates were 
incubated overnight at 4°C with primary antibody P75NTR (Promega G3231) in 
5% BSA/1X PBS. Secondary antibody goat anti-rabbit Alexa Fluor 568 (Life 
Technologies A-11011) in 5% BSA/1X PBS was added for 1 hour at room 
temperature in the dark.   
13. Proximity Ligation Assay 	
For proximity ligation assay (PLA), neurons were transfected via 
Neuromag magnetofection (Oz Biosciences) with JAK2:eGFP alone or with 
p75NTR:Flag.  Cells were fixed, permeabilized, and blocked (30 minutes, 37°C) 
in the blocking solution provided with the Duolink In Situ PLA probes (Sigma 
Aldrich). Cells were incubated overnight at 4°C in primary mouse anti-GFP 
(Abcam 1218; 1:500) and rabbit anti-Flag (Sigma Aldrich F7425; 1:250). After 
washing, cells were incubated in Duolink In Situ PLA Probes anti-rabbit PLUS 
(Sigma Aldrich DUO92002) and anti-mouse MINUS (Sigma Aldrich DUO92004) 
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for 1 hour at 37°C. Using red Duolink In Situ Detection reagents (Sigma Aldrich 
DUO92008), cells were incubated in ligation solution containing ligase (30 
minutes, 37°C), and incubated in amplification solution containing polymerase 
(80 minutes, 37°C), protected from light. Cells were washed and mounting media 
with DAPI was added to the dish. Confocal images (1 µm thick slices) were taken 
on a Zeiss LSM 710 microscrope (Zen Software) to visualize red particles 
indicating presence of (i)p75NTRJ2. ImageJ software was used for visualization. 
Schematic of PLA that detects p75NTR:Flag and JAK2:eGFP association 
(predicted distance <40 nm). 
14. Enzyme-linked immunosorbent assay (ELISA) 	
 Primary cortical neurons were co-treated with Ruxolitinib (0.05, 0.5, 5, 25, 
50 nM) and BDNF (100nM, 30 minutes).  Protein was extracted using standard 
RIPA lysis buffer technique. Equal amounts of protein were added to each well 
for ELISA detection. Phospho STAT3 levels were measured using a specific 
STAT3 (pY705) ELISA kit (Life technologies #KHO0481).  
15. EdU staining 	
The Click-iT® EdU (5-ethynyl-2 -́deoxyuridine) Alexa Fluor 594 Imaging Kit 
(Invitrogen C10339) was used to stain proliferating neurons. Live cells were 
incubated with EdU (10uM) for 2-4 hours (37°C, 5% CO2). Cells were fixed in 
3.7% formaldehyde (15 minutes, room temperature) and permeabilized in 0.5% 
Triton X-100 in 1X PBS (20 minutes, room temperature). The cells were 
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incubated in Click-iT® reaction cocktail (1X Click-iT® tris-buffered saline reaction 
buffer, 100mM CuSO4, Alexa Fluor® 594 azide, and 1X reaction buffer additive) 
for 30 minutes at room temperature, protected from light. Immunocytochemistry 
was continued with incubation overnight at 4°C with primary antibody to p291 
LSF in 1% BSA/1X PBS. Secondary antibody goat anti-rabbit Alexa Fluor 488 in 
1% BSA/1X PBS was added for 1 hour at room temperature in the dark.  
ProLong Gold Antifade Mountant with DAPI (Thermo Fisher P36941) was used 
to mount the cells for imaging.  
16. Luciferase Promoter Assay 	
GABRA1 promoter luciferase construct was previously made in lab by 
cloning GABRA1 promoter fragments (-894/+70) upstream of the luciferase gene 
in a pGL2 vector (Promega). The promoter fragment confers full promoter activity 
in primary cortical neurons. Neurons were co-transfected via calcium phosphate 
precipitation with an alpha1 promoter luciferase plasmid construct and full-length 
rat BDNF or empty vector pcDNA. Treatment with anti-BDNF (Calbiochem 
GF35L) to quench extracellular BDNF or a control normal mouse IgG (Millipore 
12-371) was started after transfection (16-24 hours). The general protocol for the 
Luciferase Assay System (Promega E1500) was used. Twenty-four hours after 
transfection, cells were lysed in the plates by adding Passive Lysis Buffer 
(Promega E153A) and shaking (20 minutes, room temperature). Cells were 
scraped, collected, and 20ul of each sample was loaded, in duplicates, onto a 
96-well plate. Using a Glomax (Promega) machine, Luciferase Assay Substrate 
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(Promega E151A/E152A) was added to each well and luminescence was 
measured for each sample. To normalize these measurements, protein 
concentration for each sample was determined using Coomassie Plus™ Protein 
Assay (Thermo Scientific #1856210).  
17. Pilocarpine-Induced Model of Status Epilepticus 	
The laboratory of Dr. Amy Brooks-Kayal performed the pilocarpine-
induced SE model in adult rats according to their protocols (Brooks-Kayal et al., 
1998b). All rats treated with a full dose of pilocarpine (350mg/kg; ip) were 
confirmed to have prolonged Stage 5 seizures on the Racine scale (Racine, 
1972). Control animals received a sub-convulsive dose of pilocarpine (35mg/kg; 
ip) and were confirmed to not have seizure activity. Rats were sacrificed 24 hours 
after induction of SE and a bilateral dissection of the hippocampus was done. 
Protein extraction was done using RIPA lysis buffer. 
18. Data Analysis and Statistics 	
 Statistical analysis was done using Microsoft Excel or Prism software. 
Significance was evaluated using a 95% confidence interval. Data are expressed 
as fold change or percentage fold change over control, with control defined as 
100% or 1. All data are expressed as mean ± standard error of the mean (SEM), 
which is the standard deviation divided by the square root of the number of 
observations per group. For data sets with two groups, data was analyzed using 
a Student’s t-test. For data sets containing three or more groups, a one-way 
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analysis of variance (ANOVA) was performed, followed by Tukey’s multiple 
comparision post-hoc test for significance between the groups.  
 For statistical notation in the text, mean is referred to as “M” and standard 
error of the mean is referred to as “SEM.” For T-tests, the t-value, a measure of 
the size difference relevative to the variation in my data sample, is reported in the 
form t(degrees of freedom) = t-value. For one-way ANOVAs, F ratio, the ratio of 
two mean square values, is reported in the form F(degrees of freedom between 
groups, degrees of freedom within groups) =  F ratio. 
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III: RESULTS: The relationship between BDNF and JAK/STAT signaling in 
neurons.  
A. Neurotrophin specific activation of ICER synthesis in neurons. 	
 Increased levels of BDNF mRNA and protein have been observed in 
animal models of TLE; however, it is not clear whether proBDNF and matBDNF 
and their receptors contribute to this effect. Previous research in our laboratories 
(Lund et al., 2008) has demonstrated that recombinant matBDNF increases 
pSTAT3 levels, which induces ICER, a potent inhibitor of genes containing cAMP 
response elements (CRE sites). We also found that STAT-dependent synthesis 
of ICER, in response to matBDNF, downregulates the number of α1 containing 
synaptic GABARs. This may be relevant to changes in brain inhibition reported 
for multiple disease endpoints, including models of TLE and human epilepsy 
patients. As BDNF exists in two isoforms in neurons, a precursor form (proBDNF) 
and a cleaved, mature form (matBDNF), we asked whether ICER induction and 
subsequent downregulation of α1 subunit gene (Gabra1) expression is specific to 
matBDNF signaling or could also be produced by proBDNF. In collaboration with 
Rebecca Benham, we show that, at the same concentration of matBDNF (50 
ng/ml or 4 nM) previously used by our labs to identify BDNF-induced JAK/STAT 
signaling in neurons (Lund et al., 2008), that recombinant proBDNF (i.e. missing 
the cleavage site necessary for production of matBDNF) activates STAT3 in a 
time-dependent manner (Figure 4A and B), induces ICER (Figure 4C), and 
downregulates levels of α1 transcript (Figure 4D). 
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Figure 4: ProBDNF activates JAK/STAT signaling and alters ICER and 
Gabra1 levels.  
In collaboration with Rebecca Benham, Ph.D.  
(A) Quantification of densitometry analysis of pSTAT3 protein in primary cortical 
neurons after 30 minutes of stimulation with vehicle or recombinant proBDNF 
(4nM). Western blot analysis was used to measure pSTAT3 expression, and is 
normalized to β-actin and total STAT3. Data are expressed relative to vehicle as 
fold change ± SEM (One-way ANOVA followed by Tukey’s Multiple Comparison 
Test, n = 3, *p < 0.05). (B) Representative Western Blot of proBDNF-induced 
changes in pSTAT3 protein levels. (C) Quantification of RT-PCR analysis using 
Taqman primers and probe specific to ICER in primary cortical neurons after 4 
hours of stimulation with vehicle (H2O) or proBDNF (4nM). ICER mRNA 
expression was normalized to cyclophilin mRNA and expressed relative to 
vehicle as a fold change ± SEM (Student’s t-test, n = 3, ***p < 0.001). (D) RT-
PCR analysis quantification using Gabra1 primers and probes specific changes 
in gene expression after 24 hours of stimulation with vehicle (H2O) or 
recombinant proBDNF. Gabra1 expression was normalized to cyclophilin, and 
expressed relative to vehicle treatment as a fold change ± SEM (Student’s t-test, 
n = 3, *p < 0.05).  
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B. Concentration-dependent affect of proBDNF on TrkB activation. 	
 Since proBDNF binds with higher affinity to p75NTR than TrkB, we asked 
whether TrkB was differentially activated upon exposure to either proBDNF or 
BDNF or whether it was activated by both proBDNF and BDNF to signal through 
the same cascade. At 4 nM, both matBDNF and recombinant proBDNF activate 
TrkB as detected using a TrkB phospho-specific antibody (Tyr490; Cell Signaling 
Technology) (Figure 5A). Decreasing the concentration about 10-fold (0.7 nM), 
there is a marked difference between the effects of the two BDNF signaling 
molecules (Figure 5B). This is consistent with an effect of 0.7 nM matBDNF, 
rather than proBDNF or nerve growth factor (NGF), in ICER induction, which is 
used as a downstream indicator of BDNF-induced JAK/STAT activation (Figure 
5C).  We also show that co-treatment with the TrkB antagonist K252A attenuates 
ICER induction (Figure 5D). Based on these observations, we conclude that 
extracellular activation of JAK/STAT signaling in neurons is dependent upon the 
activity of matBDNF at TrkB and not the action of proBDNF or NGF at p75NTR.  
Based on this result, matBDNF was used as the signaling molecule to investigate 
the function of JAK/STAT signaling in primary neurons. It is possible, however, 
that marked increases in proBDNF in response to brain injury may itself activate 
the JAK/STAT pathway via TrkB. Total TrkB full Western blots (Figure 5A and 
5B) show a truncated form around 76 kDa (indicated by *), which has been 
reported in the literature (Kryl et al., 1999). 
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Figure 5. Role for TrkB in JAK/STAT signaling.  
Primary cortical neurons were treated for 15 minutes with vehicle (H2O), 
recombinant proBDNF, or matBDNF at (A) 4 nM, or (B) 0.7 nM. Whole cell 
protein extracts from treated cells were analyzed via Western blot. Antibodies 
against pTrkB (Tyr490) (1:1000, Cell Signaling #9194), total TrkB (1:2000, BD 
Biosciences #610101), and β-actin were used. ProBDNF at 4nM activates TrkB 
indicated by pTrkB (n = 3, *p < 0.05), while at 0.7 nM it is without effect. *Note 
the faster migrating band in the full blots for total TrkB in (A) and (B) is the 
truncated form of TrkB. (C) Neurons were treated with matBDNF, proBDNF, or 
NGF (0.7 nM, 4 hours) in the presence and absence of TrkB agonist K252A (100 
nM, 1 hour) which was applied as a pre-treatment. ICER mRNA levels were then 
detected in RNA extracts via RT-PCR. matBDNF induces ICER at 0.7 nM (n = 4, 
***p < 0.001), while proBDNF and NGF do not.  (D) ICER induction is blocked by 
TrkB agonist K252A (n = 3, *p < 0.05), indicating TrkB-dependent activation of 
JAK/STAT signaling.   
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Full blots: 
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C.  Fast activation of JAK/STAT Signaling by BDNF.  	
 Our previous studies show decreased levels of Gabra1 transcripts and α1 
subunit protein, as well as α1-containing GABARs, 24 hours after primary 
neocortical or primary hippocampal cultures are treated with matBDNF (Lund et 
al., 2008). These changes are dependent on JAK/STAT signaling and consistent 
with epilepsy models. Whether or not these changes in receptor expression are 
due to an initial activation of JAK/STAT signaling by matBDNF had yet to be 
determined. We found that activation of the JAK/STAT pathway by BDNF occurs 
within minutes, where activated JAK2, indicated by the presence of 
phosphorylated JAK2 (pJAK2), is detected at 15 minutes after matBDNF 
treatment (Figure 6A). Fast activation of JAK2 is also seen in an animal model of 
SE (Figure 6B), where endogenous levels of BDNF substantially increase over 
time. To determine whether it is the initial activation of JAK/STAT signaling that 
drives changes in ICER gene expression, primary cortical neurons in culture 
were treated with matBDNF for 15 minutes, washed, and incubated in serum free 
media for 4 hours. Sister dishes were treated with matBDNF for the full 4 hours 
to serve as a positive control for ICER mRNA synthesis that we have previously 
reported. Stimulation for 4 hours with matBDNF induces a 5.3-fold increase in 
ICER expression as compared to vehicle control (H2O) whereas shorter BDNF 
stimulation (15 minutes), known to induce peak pJAK2 levels (Figure 6A), 
followed by incubation in serum free media for 3 hours 45 minutes, increases 
		78	
ICER mRNA levels by 7.6-fold (Figure 6C). Treatment with matBDNF (4 hours, 4 
nM) also caused a decrease in full-length TrkB protein levels (Figure 6D). 
D. A role for both TrkB and p75NTR in JAK/STAT signaling.  	
 Further identification of a specific role for TrkB in neuronal JAK/STAT 
signaling came from our studies using RNA silencing to deplete the levels of 
TrkB transcripts. Compared to scrambled controls, siRNAs selective for TrkB 
decrease endogenous TrkB mRNA levels by 31% in primary cortical cultures, 
consistent with the transfectional efficiency of the knockdown approach (p = 0.04; 
Figure 7A). Following 4 hours of treatment with matBDNF, selective knockdown 
of TrkB decreases levels of ICER mRNAs by 32% as compared to scrambled 
control (p = 0.0049; Figure 7B). Although levels of full-length p75NTR are low in 
the absence of BDNF as detected by western blot, marked increases in levels of 
p75NTR protein occur upon exposure to matBDNF (Figure 7C, right panel), 
suggesting that TrkB may regulate the synthesis and/or stabilization of p75NTR 
in neurons. Surprisingly, siRNAs specific to p75NTR, that reduce endogenous 
levels by 40% (p = 0.0012; Figure 7D), as compared to scrambled controls, 
produced a small (20%) but significant reduction in ICER mRNA expression (p = 
0.0336; Figure 7E). We were unable to monitor effects of gene silencing on 
protein levels so whether p75NTR protein was efficiently downregulated by 
decreasing its mRNA pool remains unknown; but provides the rationale to further 
pursue a contribution of p75NTR to the neuronal JAK/STAT response.    
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Figure 6. BDNF-induced JAK/STAT pathway activation. 
In collaboration with Rebecca Benham, Ph.D.  
Primary neurons treated with (A) matBDNF (4 nM, 15 minutes) display increased 
pJAK2 protein levels as seen by Western blot analysis (n = 3, **p < 0.01). (B) Rat 
hippocampal protein extracts have elevated levels of pJAK2 30 min and 1 hour 
post-SE induction (n = 3, **p < 0.01, ***p < 0.001). (C) To determine long-term 
effects of fast activation of JAK/STAT signaling, neurons were treated with 
matBDNF for 15 minutes, washed, and collected 4 hours later. ICER mRNA is 
induced 7.6-fold after the 15-minute treatment, greater than the 5.3-fold increase 
in ICER after 4 hours of matBDNF treatment (n = 3, *p < 0.05, **p < 0.01).  (D) 
TrkB protein levels decrease after 4 hours of matBDNF treatment (n = 3, ****p < 
0.0001). 
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Figure 7: Gene Silencing of TrkB and P75NTR.   
In collaboration with Rebecca Benham, Ph.D.  
Gene silencing using siRNA targeted against TrkB decreased (A) TrkB protein 
levels (Student’s t-test, *p < 0.05) (B) and decreased ICER mRNA expression 
(Student’s t-test, **p < 0.01). (C) BDNF treatment of primary neurons resulted in 
increased p75NTR protein (Antibody: Novus Biologicals NB110-58000; 1:1000) 
via Western blot analysis. Gene silencing of p75NTR with siRNA (D) decreased 
P75NTR protein expression (Student’s t-test, **p < 0.01) and (E) decreased 
ICER mRNA expression (Student’s t-test, *p < 0.05).  
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E.  Evidence for a p75NTR/JAK2 complex in neurons and HEK. 	
 To further delineate the respective roles of p75NTR and TrkB in 
JAK/STAT signaling, co-immunoprecipitation (co-IP) was performed to test the 
potential association of these receptors with JAK proteins in cell lines and in 
primary neuronal cultures. Employing antibodies (Abs) to the C-terminal region of 
p75NTR, generously provided by the Phil Barker laboratory (McGill) and referred 
to as p75ICD-Ab, as well as those purchased from Novus Biologicals (CAT# 
NB110-58000), we found that neuronal extracts purified using p75NTR Abs are 
enriched in JAK2 proteins and most importantly that the level of activated JAK2 
(pJAK2) within such complexes increases (90%) after 15 min of matBDNF 
stimulation (p = 0.031; Figure 8A), consistent with a role for p75NTR in 
JAK/STAT signaling. As p75NTR is considered promiscuous in its ability to 
dimerize with many other receptor types causing opposite cellular responses 
(Barker, 2009), we determined whether extracts from primary cortical neurons 
precipitated with JAK2 also contain either TrkB or sortilin. No evidence was found 
for an association with either protein using conditions where JAK2 antibodies 
precipitate p75NTR but was found for STAT3 (Figure 8B).  Therefore, when 
taken together with the results of TrkB siRNA knockdown, our results strongly 
suggest that there is a functional rather than structural link between the two 
BDNF receptor subtypes (TrkB and p75NTR) in neuronal JAK/STAT signaling.  
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F. Residues in p75NTR transmembrane domain modulate JAK2 
association.   
 The validity of the JAK2/p75NTR interaction can best be seen, however, 
using co-IP of fusion proteins JAK2:eGFP and p75NTR:Flag (gift of Phil Barker, 
McGill) after co-expression in HEK cells. As shown in Figure 8C, JAK2:eGFP is 
detected with a GFP-Ab upon co-IP using an Ab to the Flag tag in the p75NTR 
fusion protein, consistent with the association of these two endogenous proteins 
in neurons as presented in Figure 8A and 8B. To determine whether the 
transmembrane domain of p75NTR is required for its association with JAK2, we 
made two mutations in this region of the human protein: cysteine 256 and glycine 
265.  These residues aligned with rat p75NTR cysteine 257 and glycine 266, 
which have been previously shown to attenuate p75NTR dimerization at the cell 
surface as well as receptor coupling to particular intracellular signaling cascades 
(Vilar et al., 2009). Interestingly, these investigators report that the mutations do 
not affect the ability of p75NTR to form higher order oligomers in cytoplasm.  
Indicated in Figure 9A, there is a dramatic increase in the amount of JAK2 fusion 
protein that is precipitated by Flag Ab from transfected HEK that co-express 
mutant p75NTR:Flag proteins. Greatest precipitation of JAK2 is seen in extracts 
that contain p75NTR(G265I):Flag, suggesting that residues in the 
transmembrane domain, while critical for dimerization of p75NTR at the cell 
surface, may also regulate its association with JAK2 in the cytoplasm.   
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 To determine if JAK2 expression influences the oligomerization of 
p75NTR, we transfected HEK cells with either p75NTR alone, JAK2 alone, or co-
transfected with both p75NTR and JAK2, and analyzed p75NTR protein levels 
via Western blot under denaturing (+DTT) as well as non-denaturing (-DTT) 
conditions, to retain the oligomers. Transfection of wildtype p75NTR with JAK2 in 
HEK cells increases the formation of p75NTR oligomers (Figure 9B) suggesting 
that JAK2 may promote the formation of a distinct intracellular p75NTR-
containing complex. We do not know at this time whether such complexes come 
from the glycosylated form or presumed non-glycosylated form (see full gel in 
lower panel of Figure 9B). Whether or not the signal in lanes 2 and 6 of Figure 9B 
reflect the presence of endogenous JAK2 and its influence over the formation of 
p75NTR oligomers, still remains to be determined.   
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Figure 8. A P75NTR/JAK2 complex is found in neurons and HEK.  	
In collaboration with Rebecca Benham, Ph.D.  
(A) Co-IP of protein extracts from primary neuronal cultures treated with BDNF 
show increased association of endogenous p75NTR and pJAK2 (Student’s t-test, 
*p < 0.05). Pull down was done with p75NTR antibody and immunoblot was 
probed for pJAK2. (B) Further co-IPs found endogenous association of JAK2 with 
p75NTR, and p75NTR with STAT3; with no association between JAK2 and TrkB, 
or JAK2 and Sortilin, even after chemical crosslinking with DSP/DTSSP. (C) 
CoIP of protein extracts from HEK cells co-transfected with p75NTR:Flag and 
JAK2:eGFP constructs. Pulldown of proteins with anti-Flag and Western blot 
detection with anti-GFP identifies presence of p75NTR:Flag/JAK2:eGFP 
complexes. EV: Empty vector transfected negative control. In: Input sample 
made from total protein extract of p75NTR/JAK2:eGFP transfected cells. IgG: 
Control normal rabbit IgG pulldown. Flag: Pulldown with anti-Flag antibody.  
*Note that the strong bands around 50 and 20 kDa represent heavy and light 
chains of IgG. 
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Full blot: 
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Figure 9: Transmembrane domain p75NTR residues modulate JAK2 
association.   
(A) CoIP of HEK cells transfected with JAK2:eGFP and either 
(C256A)p75NTR:Flag or (G265I)p75NTR:Flag. Pulldown of proteins with anti-
Flag and Western blot detection with anti-GFP indicates that mutations in the 
p75NTR:Flag transmembrane domain increase JAK2:eGFP precipitation. Lane 
labels: In: Input sample made from total protein extract of p75NTR/JAK2:eGFP 
transfected cells. IgG: Control normal rabbit IgG pulldown. Flag: Pulldown with 
anti-Flag antibody. Inputs samples (A middle panel) were via Western blot for 
Flag and β-actin to check equal transfection. *Note that the strong bands around 
50 and 20 kDa on the full blot represent heavy and light chains of IgG. (B) 
Protein samples from HEK cells transfected with either p75NTR:Flag (P75), 
JAK2:eGFP (JAK2), or both p75NTR:Flag and JAK2:eGFP (P75/JAK2) were 
compared to non-transfected (NT) controls. The Western blot was probed with a 
p75NTR antibody (p75ICD, gift of P. Barker). Samples were made with 
denaturing (+DTT) as well as non-denaturing (-DTT) conditions to visualize dimer 
and oligomer formation. Transfection of wildtype p75NTR with JAK2 in HEK cells 
increases the formation of p75NTR oligomers. 
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A. 
 
 
 
Full blot: 
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B. 
 
 
 
Full blot: 		
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G.  Detection of p75NTR/JAK2 complexes in neuronal processes, cell body, 
and nucleus. 
 As a first step to examine where p75NTR/JAK2 complexes are located in 
the cell, primary cortical neurons were transfected with JAK2:eGFP fusion 
proteins and immunocytochemistry was performed using antibodies to 
endogenous p75NTR.  As can be seen in Figure 10A-10C, where a single z slice 
of two representative neurons are displayed, neurons can differ in the localization 
of both JAK2:eGFP and p75NTR.  In addition, not all JAK2:eGFP is associated 
with p75NTR. There are discrete pockets of co-localization of p75NTR and 
JAK2:eGFP seen in a single Z slice (Figure 10C) and Z-sum (Figure 10D), as 
well as in Figure 10E where highest intensity of co-localized points is 
pseudocolored in green across the Z stack.  
 
H.  Detection of p75NTR/JAK2 complexes in neuronal processes, cell body, 
and nucleus using Proximity Ligation Assay (PLA). 
 To test for a direct association between p75NTR and JAK2, the proximity 
ligation assay (PLA, see Methods) was performed using primary cortical neurons 
transfected with the expression constructs p75NTR:Flag and JAK2:eGFP in 
intact cells. PLA can detect association between proteins if they are within 30-40 
nanometers (nm) using secondary antibodies conjugated to complementary 
oligonucleotides and detected by in situ hybridization to the products of rolling 
circle PCR (Figure 11A). As can be seen in Figure 11B and 11D, PLA reveals 
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that p75NTR/JAK2 complexes (red signals) can form in neurons and that their 
co-localization and distribution is consistent with detection of endogenous 
p75NTR and JAK2:eGFP (Figure 10). Detection of native fluorescence from 
JAK2:eGFP in the cell body of the z-stack always occurs prior to detection of 
PLA signals, suggesting that the majority of the PLA detected interactions are in 
the cytoplasm rather than close to the cell membrane, as expected for a 
transmembrane receptor. Also note the presence of red signals in the nucleus 
(blue stain) of the magnified Z slice (1 micron thickness) in Figure 11B and the 
right panel orthogonal views of the full stack that show the red signal sandwiched 
between layers of the native fluorescence from JAK2:eGFP (Figure 11B, right 
panel). No red signal, however, is detected when neurons are transfected with an 
eGFP transgene instead of p75NTR:eGFP (Figure 11C). Detection of PLA 
signals specific to two transfected primary cortical neurons with z-slice 
summation is also shown (Figure 11D). The constellation of evidence including 
co-IP, overlapping fluorescent signals specific to endogenous p75NTR and 
JAK2:eGFP, and the close proximity of p75NTR:flag and JAK2:eGFP as 
detected by PLA, strongly suggest that neurons contain an intracellular 
p75NTR/JAK2 complex that is a component of the JAK/STAT pathway in 
neurons. We shall refer to this complex as the signalsome (i)p75NTRJ2 
throughout the remainder of the manuscript where (i) represents the intracellular 
presence of the complex and (J2) the association of p75NTR with JAK2.   
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Figure 10. Confocal analysis of p75NTR/JAK2-eGFP complexes.  
Primary neuron cultures were transfected with JAK2:eGFP, fixed, permeabilized, 
and labeled for endogenous p75NTR with a rabbit primary antibody to p75NTR 
(1:500, Promega #G323A), followed by secondary with goat anti-rabbit Alexa 
Fluor 568 (Molecular Probes #A-11011). Images for separate (A) JAK2:eGFP 
(green) and (B) endogenous p75NTR (red) combined in (C) to show co-
localization (white arrows). (D) Z-sum (1 µm thick slices) of confocal image stack 
and (E) Z slice-summation of co-localized points. JAK2:eGFP: green. p75NTR: 
red. Co-localization: yellow. Magnification: 63x. Scale bar = 50µm  
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A.       C. 
 
B.        D. 
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Figure 11. p75NTR-Flag and JAK2-eGFP complex in situ.  
Neurons were cotransfected with JAK2:eGFP and p75NTR-Flag, fixed, 
permeabilized, and PLA assay (A) was conducted with anti-GFP and anti-Flag 
antibodies to visualize interaction between JAK2:eGFP and p75NTR-Flag. (B) 
Single slice, PLA of neuron transfected with JAK2:eGFP (green) and p75NTR-
Flag; PLA complex is visualized by red dots. DAPI: blue. Right; orthogonol view 
showing all slices. (C) Single slice, negative control transfected with non-specific 
pmaxGFP and p75NTR-Flag. Note that there are no red puncta. Right; 
orthogonol view showing all slices. (D) Detection of PLA signals specific to two 
transfected primary cortical neurons with z-slice summation (set at signal 
intensity, ImageJ) Scale bar for (B) and (C) = 20 µm. Scale bar for (D) = 50µm. 
Magnification: 63x.   
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I.  Inhibition of JAK2 reduces the formation of (i)p75NTRJ2. 	
 Collaborative studies in our laboratory previously reported that treatment 
with the JAK/STAT inhibitor WP1066 reduces the frequency of spontaneous 
seizures in pilocarpine-induced SE rats (Grabenstatter et al., 2014). SE rats 
treated with WP1066 also had reduced mRNA expression of STAT3-target 
genes, including ICER, in the DG compared to control-treated SE rats. Since 
JAK/STAT inhibition can occur through either deactivation or degradation of JAK, 
we wished to determine the mechanism of action of WP1066 as seen in our 
primary neuron cultures. Since ICER expression is increased after just 4 hours of 
BDNF treatment, we expected to see an effect of WP1066 at a similar time 
period. Indeed, after 5 hours treatment, WP1066 significantly degraded total 
JAK2 levels, and this effect could not be rescued with BDNF treatment (Figure 
12A). Interestingly, a more potent JAK/STAT inhibitor, ruxolitinib, did not degrade 
JAK2 levels (Figure 12B). These results suggest that WP1066 inihibits JAK 
mainly through degradation. 
 We previously showed that pyridone 6, a selective JAK2 inhibitor, blocks 
STAT3 phosphorylation, ICER induction by BDNF, and the subsequent 
downregulation of α1 subunit mRNA levels in vitro and in vivo (Lund et al., 2008) 
and demonstrated that treatment in vivo with an additional JAK2 inhibitor, 
WP1066, attenuates the development of spontaneous seizures after SE 
(Grabenstatter et al., 2014). Here, we employ ruxolitinib (RUXO), a high affinity 
JAK2 inhibitor, currently used in the clinical treatment of myeloproliferative 
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neoplasms (Mascarenhas and Hoffman, 2012), and found that it blocks STAT3 
phosphorylation in primary neurons with high-affinity (Ic50 = 10 nM; Figure 13A).  
We also asked whether RUXO interferes with (i)p75NTRJ2 formation, either 
because activated JAK2 is necessary to build the complex or because RUXO 
binds to the surface that is important for JAK2/P75NTR interactions, an area of 
ongoing investigation in our laboratories. As can be seen in Figure 13B, there is 
a marked decrease in JAK2-GFP precipitated with the Flag antibody after 100nM 
RUXO treatment of HEK cells, when compared to DMSO vehicle (n = 3, 
normalized to input levels of JAK2:eGFP, *p < 0.05). These results suggest that 
RUXO not only inhibits JAK2 phosphorylation, as a well described JAK2 inhibitor 
(Grabenstatter et al., 2014), but also formation of (i)p75NTRJ2 in transfected 
HEK cells and primary cultured neurons (Figure 13C).   
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Figure 12: Long-term treatment with WP1066 degrades JAK2 protein.  
Primary rat cortical neurons were pretreated for 1 hour with WP1066 (10µM, 
Millipore #573097), Ruxolitinib (10µM), or vehicle (DMSO), before being treated 
with BDNF (5ng/ml) or vehicle (water) for 4 hours. Cells were collected for protein 
extraction and analysis via Western blot. Blots were probed with JAK2 antibody 
(1:1000, Cell Signaling #3230) and βactin. JAK2 levels were normalized to βactin 
and expressed as fold change over vehicle (DMSO/Water). (A) WP1066 
treatment significantly reduced JAK2 protein levels, even in the presence of 
BDNF. One-way ANOVA was conducted with Tukey’s post-hoc test between 
groups [F(3,11) = 135.7, p < 0.0001]. (B) Ruxolitinib did not degrade JAK2 
protein levels (n = 3). RUXO alone: M = 2.09, SEM = 0.67; RUXO and BDNF: M 
= 2.43, SEM = 1.43. Data are expressed as mean ± SEM. 
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Figure 13: JAK inhibitor ruxolitinib (RUXO) blocks (i)p75NTRJ2 formation. 
 
(A) Determination of Ic50 in vitro. Primary cortical neurons were co-treated with 
RUXO (0.05, 0.5, 5, 25, 50 nM) and BDNF (100 nM, 30 minutes). Phospho 
STAT3 levels were measured using a STAT3 (pY705) ELISA kit (Life 
technologies #KHO0481). pSTAT3 levels are expressed as a percentage of the 
full response to BDNF treatment alone, and plotted against the log[RUXO].  Ic50 
calculated = 8.58 nM.  Data are expressed as mean ± SD of duplicate samples. 
(B) Co-IP of proteins from HEK cells transfected with JAK2-eGFP and 
p75NTR:Flag either vehicle (DMSO) or RUXO (100 nM). Treatment specifically 
decreases JAK2:eGFP/p75NTR:Flag association (n = 3, normalized to input 
levels of JAK2:eGFP, *p < 0.05). (C) PLA with vehicle (DMSO) treatment versus 
RUXO (100nm), which attenuates complex formation. Scale bar = 20 µm. 
Magnification: 63x 
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J.  A role for intracellular proBDNF in the JAK/STAT pathway of neurons. 
 Primary neurons increase their levels of matBDNF mRNAs in response to 
chronic matBDNF treatment in culture suggesting that intracellular levels of 
matBDNF can be quite high during brain insult (Greenberg et al., 2009). 
However, in collaboration with our colleagues in the Dr. Brooks-Kayal laboratory 
(U. of Colorado) we have just reported that proBDNF rather than matBDNF is 
increased after seizure activity in a TLE model of epilepsy. Our laboratories 
reported that proBDNF levels are elevated in the hippocampus of pilocarpine-
induced SE mice within 3 hours after onset, persisisting through 24 hours, and 
peaking at around 3 days after SE onset (Thomas et al., 2016). There is also a 
reduction in tPA and increased PAI-1, two enzymes involved in the proteolytic 
processing of proBDNF (Thomas et al., 2016) suggestive of a mechanism for 
increased proBDNF rather than matBDNF in vivo.  
 At the higher doses of signaling molecule used in our studies, we showed 
that proBDNF acts on the matBDNF high affinity receptor, TrkB (Figures 4 and 
5). As a first step to understand the importance that intracellular BDNF may play 
in prolonged BDNF-induced JAK/STAT activation and to test the increase in 
intracellular proBDNF seen in vivo, we asked whether overexpression of 
proBDNF in transfected neurons would affect the activity of the GABRA1 
promoter as assayed in primary cortical cultures. Cultures were co-transfected 
with GABRA1p-luciferase constructs with either empty vector or a pCAG 
promoter driven transgene that codes for full length (proBDNF). Application of 
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anti-BDNF blocking antibody, intended to block extracellular BDNF, blocks both 
TrkB activation (Figure 14A) and induction of ICER [t(2) = 3.7, p = 0.03] (Figure 
14B) as assayed by real-time PCR when BDNF is applied to the media and 
serves as a positive control for the promoter studies with the BDNF transgene. 
Using a promoter assay (Figure 14C), our results clearly indicate that proBDNF 
delivered in this context is able to downregulate GABRA1 promoter activity [t(4) = 
9.2, p = 0.0008], a hallmark of JAK/STAT activation in neurons (Figure 14D) and 
that such downregulation occurs even when antibodies to BDNF block activation 
of cell surface BDNF receptors [t(4) = 2.7, p = 0.03] (Figure 14E).  
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Figure 14. Overexpression of full length BDNF decreases GABRA1promoter 
activity.  
(A) Anti-BDNF treatment overnight prevented activation of TrkB receptor, even 
when treated with recombinant BDNF, as observed by protein levels of 
phosphoTrk in Western blot. (B) In total RNA extracts from neurons co-treated 
with anti-BDNF or vehicle (normal mouse IgG) and matBDNF (4 nM, 4 hours), 
anti-BDNF significantly reduced BDNF-induced ICER expression (Student’s t-
test, *p < 0.05). (C) Promoter assay (schematic shown) found that (D) GABRA1 
promoter luciferase activity decreased in primary neurons co-transfected with the 
full length BDNF transgene when compared to empty vector (Student’s t-test, 
***p < 0.001). (E) Anti-BDNF treatment, which quenches extracellular BDNF in 
the media, of neurons transfected with the BDNF transgene does not reverse 
downregulation of GABRA1 promoter luciferase activity, suggesting a role for 
intracellular BDNF (Student’s t-test, *p < 0.05).  
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IV. RESULTS: BDNF-induced selective phosphorylation of LSF and its 
association with neurogenesis and status epilepticus. 
A.  BDNF induces phosphorylation of p291 LSF through MEK signaling. 	
 Molecular changes that occur in epilepsy models and in human patients 
include a robust increase in BDNF signaling. Since BDNF is involved in neuronal 
survival, differentiation, and neurogenesis, we hypothesized that BDNF signaling 
is linked to the activation of LSF, a ubiquitous cell cycle regulator. To examine 
this possibility, primary cortical and hippocampal neurons were treated with 
mature recombinant human BDNF (50ng/ml, Millipore) for 4 hours, a time point 
that we previously reported produces a peak induction in BDNF-induced ICER 
transcription. As shown in Figure 15A, under these same conditions, BDNF 
markedly increases levels of p291 LSF (cortical M=158%, SEM=14%; 
hippocampal M=174%, SEM=17%) over vehicle (M=100%, SEM=0%) in cortical 
[t(6)=4.014, p=0.007] and hippocampal [t(3)=4.270, p=0.024] neurons with no 
change in p309 or total LSF, suggesting that phosphorylation of LSF at serine 
291 is controlled by the same BDNF signaling that regulates the expression of 
GABARs after SE. The antibody for p291 LSF also recognizes higher molecular 
weight bands right above 60 kDa, and a large band above 225 kDa, as seen in 
the full Western blot (indicated by *). While we did not quantify this change, these 
bands are specific to p291 LSF and seem to increase with BDNF treatment. The 
ladder pattern of the bands right above 60 kDa may indicate LSF is conjugated to 
small ubiquitin-like modifiers (SUMOs), a modification known as SUMOylation, 
		111	
since LSF is a reported substrate of SUMO-2 in U2OS cells, and is increased in 
response to heat shock (Golebiowski et al., 2009).  
 To determine whether increases in p291 LSF are specifically dependent 
on BDNF signaling, we tested whether phosphorylation of LSF at this site would 
also occur in a cellular model of generalized neuronal depolarization utilizing 
potassium chloride (KCl) (Toescu, 1999). Primary neuronal cultures were treated 
with KCl (20 mM) for 2 hours followed by total protein extraction. Western blot 
analysis revealed no change in p291 LSF protein levels between the vehicle 
(water) and KCl treatment groups (Figure 15B), suggesting that presence of p291 
LSF is dependent on BDNF signaling and not on a general change in the 
depolarization state of the neuron.  
 From our previous studies, and those of our colleagues, we know that 
BDNF signaling occurs through two major pathways that may be relevant for 
epileptogenesis, MAPK/ERK and JAK/STAT. In order to determine which 
downstream pathway is responsible for inducing p291 LSF, neurons were 
pretreated with a MEK inhibitor, U0126 (20 µM), or a JAK/STAT inhibitor, P6 (500 
nM) prior to addition of recombinant mature BDNF. Both MEK1 and MEK2 are 
inhibited by U0216, a MAPK/ERK kinase inhibitor, and pre-treatment before 
BDNF application blocks BDNF-induced phosphorylation of LSF at p291 
[F(3,20)=8.37, p=.0008] (Figure 15C). Pyridone 6 (P6) is a potent ATP-
competitive inhibitor of JAK1, 2, and 3. Unlike U0126, JAK/STAT inhibition with 
P6 did not block BDNF-induced phosphorylation of LSF at p291 (Fig. 15D), 
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suggesting that this site-specific post-translational modification does not require 
BDNF activation of JAK/STAT signaling but rather activation of the MAPK/ERK 
pathway already identified as required in cancer cell lines (Pagon et al., 2003). 
  
		113	
Figure 15: BDNF induces phosphorylation of p291 LSF.   
(A) Primary neuron cultures treated with BDNF showed an increase in p291 LSF 
compared to vehicle, but no increase in total LSF or p309 LSF. Student’s t-test 
was used to analyze cortical (n=7, **p<0.01) and hippocampal (n=4, *p<0.05), 
cells separately and data are expressed as mean ± SEM. Full blot shows higher 
molecular weight bands in a ladder pattern right above 60 kDa, and a large band 
above 225 kDa (indicated by *), which seem to increase with BDNF treatment. 
(B) Potassium chloride (KCl, 20 mM; Boston BioProducts MT-250) treatment did 
not induce p291 LSF. Representative data is for two hours treatment at DIV 7. 
Four hour treatment at DIV 14 also shows no change in p291 LSF. (C) MEK 
inihibitor (U0216) pretreatment blocked p291 LSF induction by BDNF. Data were 
analyzed by one-way ANOVA and are expressed as mean ± SEM (**p<0.01 
***p<0.001). (D) JAK inhibitor (P6) pretreatment did not block p291 LSF 
induction. Total protein extracts analyzed via Western blot and probed with 
polyclonal rabbit antibodies raised against phospho-LSF S291 (1:3000), 
phospho-LSF S309 (1:300), and total LSF (1:500). Bands were normalized to β 
actin (Sigma Aldrich A5441; 1:5000). Full blots are shown for each antibody in 
this figure and following figures. Full blots for Total LSF and β actin are not 
shown because only one band was detected.  
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B. P291 LSF is not expressed in proliferating cells. 
 Since phosphorylation of LSF has not been studied in neurons, we set out 
to characterize the expression of p291, p309, and total LSF, which includes 
phosphorylated and unphosphorylated LSF, in primary neuronal cultures. We 
neurons labeled with an antibody to NeuN and an antibody to either p291 LSF 
(Figure 16A), p309 LSF (Figure 16B), or total LSF (Figure 16C). As expected, 
total LSF is found in all cells as it is ubiquitously expressed. However, p291 LSF 
is not found in every cell that contains LSF, suggesting that its presence is post-
translationally regulated in primary neurons (Figure 16). Given that LSF is a 
regulator of the cell cycle and survival (Hansen et al., 2009; Veljkovic and 
Hansen, 2004) we hypothesized that a change in the state of LSF in the brain 
may contribute to the regulation of neurogenesis. To address the potential link 
between neurogenesis and LSF, LSF expression in neurons was examined 
during different states of cellular differentiation. Using immunocytochemistry, 
neurons were co-labeled with LSF and a variety of neuronal markers for 
proliferating and mature neurons.  
To mark proliferating or dividing neurons, we used an EdU 
immunocytochemistry assay (Invitrogen), as an alternative to the use of BrdU. 
EdU is a nucleoside analog of thymidine and is incorporated into DNA during 
active DNA synthesis (Salic and Mitchison, 2008).  To obtain a signal in vitro, a 
copper catalyzed covalent reaction occurs between a picolyl azide containing an 
Alexa Fluor 594 (red) dye and an alkyne containing the EdU. Labeling primary 
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hippocampal and cortical neuronal cultures with p291 LSF and EdU (Figure 17), 
EdU-positive cells were imaged that contain barely detectable levels of p291 LSF 
when compared to EdU-negative cells. These results suggest that 
phosphorylation at serine 291 does not occur in actively dividing neurons. There 
are also populations of cells, indicated by DAPI staining alone, that do not have 
p291LSF or EdU.  While we only show this in the merged image of Figure 17, we 
did see this population throughout our ICC experiments.  
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Figure 16: p291 LSF, p309 LSF, and Total LSF are present in neurons.  
Immunocytochemistry in primary cortical neuron cultures used antibodies to 
NeuN (1:250; mouse polyclonal, Chemicon, red) and either (A) p291 LSF, (B) 
p309 LSF, or (C) Total LSF (green, all from Ulla Hansen’s lab) overnight.  All 
forms of LSF co-localized with NeuN-positive neurons. Secondary antibody goat 
anti-rabbit Alexa Fluor 488 (Life Technologies A-11008) and anti-mouse IgG 
Texas Red (Vector TI-2000) in 1% BSA/1X PBS was added for two hours at 
room temperature in the dark. Images were taken at 20x magnification. Scale bar 
= 100 µm. 
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Figure 17: p291 LSF is not associated with proliferating neurons.   
Live primary neuron cultures were stained for EdU before fixing, permeabilizing, 
and incubating with primary antibody to p291 LSF. EdU-positive, proliferating 
neurons (red) did not co-label for p291 LSF (green). Secondary antibody goat 
anti-rabbit Alexa Fluor 488 (Life Technologies A-11008) 1% BSA/1X PBS was 
used to recognize p291 LSF antibody and visualize. ProLong Gold Antifade 
Mountant with DAPI (Thermo Fisher P36941) was used to mount the cells for 
imaging. Images were taken at 20x magnification. Scale bar = 100 µm. EdU: red. 
DAPI: blue. P291 LSF: green.  
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C. P291 LSF is expressed in neurons throughout neurogenesis. 	
Nestin is an intermediate filament expressed in neural precursor cells 
(Lendahl et al. 1990) as well as proliferating neurons in the adult brain that 
develop into mature neurons and astrocytes (Reynolds and Weiss 1992). Using 
immunocytochemistry to detect Nestin-positive cells, we found that p291 LSF 
was present in Nestin-positive neurons (Figure 18A), suggesting that 
phosphorylation at serine 291 is expressed in immature neurons or precursors. 
PSA-NCAM is highly expressed in newly generated and developing granule cells 
in the dentate gyrus of the hippocampus (Seki and Arai, 1991) and persists in 
young post-mitotic neurons (Seki 2002a). Primary neurons were labeled for PSA-
NCAM and p291 LSF, and p291 LSF co-labels with PSA-NCAM-positive cells 
(Figure 18B). As mitogen activated protein 2 (MAP2) is expressed predominantly 
in the dendrites of mature neurons (Cáceres et al., 1986) we asked whether p291 
levels might be high in those cells where MAP2 is present. Primary neuronal 
cultures labeled for both MAP2 and p291 LSF display the highest levels of p291 
LSF (Figure 18C), further suggesting that presence of p291 promotes a post-
mitotic, mature neuronal phenotype. Together, the results of 
immunocytochemistry strongly suggest that phosphorylation of LSF at serine 291 
is suppressed during proliferation, but exists in precursor neurons, newly 
generated neurons, and persists throughout neuronal maturity. 
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Figure 18: p291 LSF expression persists throughout neurogenesis. 
Primary neurons were stained for different proliferation markers. Secondary 
antibody goat anti-rabbit Alexa Fluor 488 (Life Technologies A-11008) and/or 
anti-mouse IgG Texas Red (Vector TI-2000) in 1% BSA/1X PBS was added for 
two hours at room temperature in the dark. ProLong Gold Antifade Mountant with 
DAPI (Thermo Fisher P36941) was used to mount the cells for imaging. DAPI: 
blue. P291 LSF: green.  (A) Nestin-positive, neural precursor cells (red), 
contained p291 LSF (green). (B) PSA-NCAM positive, newly generated neurons 
(red), co-labeled for p291 LSF (green).  (C) Microtubule associated protein 2 
(MAP2)-positive, mature neurons (red) co-labeled for p291 LSF (green). Images 
were taken at 10x magnification. Scale bar = 100 µm. 
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C. Increased p291 LSF in the hippocampus of the pilocarpine-induced 
model. 
 To determine whether p291 LSF may be linked to epileptogenesis, given 
its regulation by BDNF in primary cell cultures, LSF protein levels were examined 
24 hours after pilocarpine-induced SE in rats. Levels of LSF were detected in 
hippocampal tissue microdissected by our colleagues in Dr. Amy Brooks-Kayal’s 
laboratory at University of Colorado. Compared to control animals (n=4, M=100% 
SEM=0%), animals 24 hours after SE exhibit higher levels of p291 LSF (n=4, 
M=118% SEM=5%) in the hippocampus [t(3)=3.6, p=0.036] (Figure 19), 
suggesting that specific regulation of LSF phosphorylation induced by a rise in 
BDNF is also associated with the hyperactive state that is the product of 
prolonged seizure activity. Interestingly, the protein samples from the 
hippocampal tissue do not have the larger kDa ladder pattern of bands, which 
may be SUMOylation, seen in Figure 15A. 
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Figure 19: Elevated levels of p291 LSF in hippocampus of SE model rats. 
The Amy Brooks-Kayal laboratory performed the pilocarpine-induced SE in adult 
rats according to standard protocols. All rats treated with a full dose of 
pilocarpine (350 mg/kg; ip) were confirmed to have prolonged Stage 5 seizures 
on the Racine scale. Control animals received a sub-convulsive dose of 
pilocarpine (35 mg/kg; ip).  Rats were sacrificed 24 hours after induction of SE 
and a bilateral dissection of the hippocampus was done for protein extraction.  
Total hippocampal protein was analyzed via WB and probed for p291 LSF, total 
LSF, and β actin loading control.  Levels of p291 LSF were normalized to total 
LSF. Hippocampal protein from SE animals has increased levels of p291 LSF 
normalized to total LSF, when compared to control animals (n=4,  *p<0.05). 
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D. P291 LSF is higher in adult brain regions containing newly generated 
neurons. 
 To learn more about LSF’s association with adult neurogenesis, levels of 
phosphorylated LSF were compared across brain regions where adult 
neurogenesis has been reported, such as the hippocampus, and where newly 
generated neurons are found to migrate, the olfactory bulb. We compared the 
levels of p291 LSF in these two brain regions to an area that contains mainly 
mature neurons, the prefrontal cortex. Although not understood at this time, p291 
LSF in adult rat brain extracts appears as a doublet around 57 kDa in the 
hippocampus and olfactory bulb, where there are high levels of neurogenesis but 
not in cortex or in extracts of primary neuronal cultures. We analyzed p291 LSF 
at the faster migrating band of the doublet (see full blot in Figure 20) because it 
aligned with the total LSF single band. Levels of p291 LSF were highest in the 
olfactory bulb, followed by the hippocampus, with lowest levels in the prefrontal 
cortex [F(2,6)=18.85, p=.002] (Figure 20). This is surprising given that p291 is 
selectively found in neurons that express MAP2 and are post-mitotic, suggesting 
that it may play a role in transitioning cells into maturity rather than maintaining 
the mature phenotype. 
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Figure 20: Expression of p291 LSF in adult rat brain areas of neurogenesis. 
For adult brain extracts, we saved the brains from adult female rats used for 
embryo dissection. Protein was extracted from bilateral dissections of the 
prefrontal cortex, hippocampus, and olfactory bulb tissue. Total protein was 
analyzed via WB and probed for p291 LSF and β actin loading control. P291 LSF 
levels were highest in olfactory bulb, followed by hippocampus, while lowest 
levels were in the cortex. P291 LSF in the adult rat brain extracts show a doublet 
around 57 kDa, which is not present in primary neuron cultures. Data were 
analyzed via one-way ANOVA followed by Tukey’s post-hoc test for differences 
between groups (*p<0.05, **p<0.01). 
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V: DISCUSSION 
A. Neurotrophin signaling controls JAK/STAT activation in neurons. 
 Results of our studies suggest that BDNF signals through two distinct 
neurotrophin receptor mediated pathways to regulate levels of GABAR subunit 
expression. Such BDNF-induced changes in receptor subunit levels occur in 
humans and in animal models of TLE, where an upregulation of α4 and a 
downregulation of α1 subunit mRNA levels and protein are observed in dentate 
granule cells after prolonged seizures (Brooks-Kayal et al., 1998b; Lund et al., 
2008). Mature BDNF (matBDNF) signals through the TrkB receptor to activate 
MAPK, which increases the synthesis and binding of Egr3 to early growth 
response elements in the Gabra4 promoter (Roberts et al., 2006; Roberts et al., 
2005). Concurrently, we now suggest that BDNF activates the JAK/STAT 
pathway, potentailly through a novel p75NTR/JAK2 complex ((i)p75NTRJ2) that 
induces ICER expression, which in turn heterodimerizes with pCREB reducing 
the expression of the most abundant GABAR subunit, α1 (Lund et al., 2008; Hu 
et al., 2008). Given our previous findings that inhibition of the JAK/STAT pathway 
prevents seizure induced changes in ICER and Gabra1 expression (Lund et al., 
2008), it was critical to understand how BDNF mediates this pathway that 
contributes to altered GABAR expression in the diseased brain (Brooks-Kayal et 
al., 1998b). 
 Traditionally, activation of the JAK/STAT pathway has been associated 
with cytokine receptor signaling. As part of the inflammatory pathway, cytokines 
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contribute to the fast acting innate immune response by activating signaling 
cascades that mediate a number of downstream genes involved in cell 
proliferation, differentiation, immune response, and apoptosis (Darnell et al., 
1994; Harrison, 2012; Vezzani and Granata, 2005). The JAK/STAT pathway has 
distinct roles in the CNS, where it is involved indevelopment, hormone release, 
inflammation or tumorigenesis (Nicolas et al., 2013). JAK/STAT signaling can 
also influence glial differentiation (Bonni et al., 1997), proliferation of NSCs 
(Bauer, 2009; Gómez-Nicola et al., 2011), neurogenesis (Müller et al., 2009), and 
neuronal survival (Schindler et al., 2007). Studies in our laboratory have 
identified another role for JAK/STAT signaling pathway in the CNS, where we 
have have previously demonstrated that BDNF-induced STAT signaling is a 
critical mediator of Gabra1 expression following SE (Lund et al., 2008).  
 In these studies, we provide further evidence and characterization of 
BDNF-induced JAK/STAT signaling, as fast and transient increases in pJAK2, 
the most abundant JAK isoform in the brain, occur following BDNF treatment and 
SE (Figure 3A-B). While glial-specific increases in JAK/STAT activation have 
previously been reported in a kainate model of TLE (Choi et al., 2003) our 
cultures are predominately neuronal, suggesting that BDNF-induced increases in 
JAK/STAT signaling are attributed at least in part to neurons. Furthermore, these 
short-term increases in JAK/STAT activation detected in response to BDNF 
stimulation are sufficient to induce the downstream changes in ICER expression 
we observe hours later (Figure 3C). This suggests that minutes of exposure to 
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matBDNF can leave its imprint on genome expression in a manner relevant to 
the remodeling of brain systems, even as levels of TrkB are downregulated 
(Figure 3D) and consistent with our in vivo findings that transient blockade of 
JAK2 after SE by WP1066 causes profound effects on seizure susceptibility 
(Grabenstatter et al., 2014). 
 Although still controversial in the field, the fate of a neuron may be 
controlled by the BDNF isoform, either the translated precursor proBDNF or the 
cleaved post-translational matBDNF, and the receptor that is activated. A yin and 
yang theory for BDNF action has developed over the years, suggesting that a 
balance is struck between matBDNF signaling through TrkB to promote cell 
survival, while proBDNF signals through p75NTR, complexed with sortilin, to 
promote apoptosis (Teng et al., 2005). Alterations in proBDNF and matBDNF 
have been reported in a pilocarpine model of TLE (Unsain et al., 2008), although 
limitations in interpretation may remain based on antibody specificity, region 
selective expression and release. With increases in both BDNF isoforms reported 
in response to SE, we investigated whether proBDNF could also activate 
JAK/STAT signaling employing a standard concentration reported in the literature 
(50ng/ml, or 4nM). Using a mutant form of proBDNF, which has a valine 66 to 
methionine SNP (Chen et al., 2004) that prevents cleavage, we found transient 
increases in pSTAT3 levels, as well as downstream changes in ICER and 
Gabra1 mRNA expression, suggesting that stimulation with either BDNF isoform 
is capable of activating the JAK/STAT pathway (Figure 1). However, as we have 
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demonstrated, proBDNF does so via the TrkB receptor. This effect of proBDNF is 
diminished when we drop the concentration of proBDNF and matBDNF 10-fold 
(to 5ng/mL, or 0.7nM), a concentration at which only matBDNF significantly 
activates JAK/STAT signaling. These findings suggest that TrkB indeed is 
coupled functionally to JAK/STAT activation at the membrane. Interestingly, 
during the course of our studies it was reported that only proBDNF activates the 
JAK/STAT pathway in two-week old hippocampal neurons. It was also suggested 
that such activation was due to p75NTR acting at the membrane (Riffault et al., 
2014).  It is difficult to compare our findings with those of Riffault and colleagues 
as they did not directly measure whether proBDNF was acting at TrkB, such as 
could be accomplished by examining phospho-TrkB levels after proBDNF 
treatment in their system.  Instead, lack of TrkB in the pathway was attributed to 
no effect of proBDNF on levels of phospho-CREB that increase using matBDNF. 
This does not rule out TrkB-mediated JAK/STAT responses as the two signaling 
molecules, proBDNF and matBDNF, may differentially regulate the 
pharmacodynamics of TrKB, and therefore, the effector pathway to which they 
are coupled. Whether or not their results identify a distinct property of JAK/STAT 
signaling in mature neurons versus developing neurons remains to be 
determined. These findings add another dimension to the complexity of this 
important BDNF-induced signaling pathway in the nervous system and the need 
to carefully evaluate each recombinant BDNF reagent for its receptor selectivity 
in control assays.   
		140	
 Along with SE-induced increases in BDNF, changes in TrkB and p75NTR 
expression are also reported in animal models of epilepsy (Bengzon et al., 1993; 
Unsain et al., 2008; Kaplan and Miller, 2000). As studies in primary neuronal 
cultures reported that chronic stimulation with BDNF for several days led to a 
decrease in TrkB mRNA and protein expression (Knusel et al., 1997), we 
hypothesized that altered neurotrophin receptor expression in neurons may be 
mediated by BDNF. We examined this phenomenon at a time point when BDNF-
induced changes in ICER expression are observed (4 hours), and found that 
matBDNF regulates the levels of its own receptors, by increasing p75NTR and 
decreasing TrkB (Figures 3D and 4C). Again, such feedback regulation by BDNF 
was ascribed by Riffault and colleagues (Riffault et al., 2014) to p75NTR rather 
than TrkB, suggesting that they either missed the participation of TrkB in the 
JAK/STAT signaling cascade, or that BDNF receptors can swap their roles in the 
JAK/STAT pathway dependent upon the expression levels of different BDNF 
isoforms. This intriguing possibility will be explored in future studies.  
 Having observed that TrkB and p75NTR protein expression is altered 
following BDNF stimulation, the roles of TrkB and p75NTR in the BDNF-induced 
JAK/STAT signaling pathway were examined in more detail. We hypothesized 
that siRNA knockdown of either receptor TrkB or p75NTR would influence the 
expression of ICER. We found that siRNA knockdown of either mRNA species 
TrkB or p75NTR reduces BDNF-induced ICER synthesis (Figure 4), suggesting 
that both receptors may play a role in a1 subunit decreases. Whether there is a 
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difference in the relative contribution of each receptor to BDNF-induced ICER 
synthesis remains to be determined. However, our current results strongly 
suggest that both receptor systems are part of the JAK/STAT pathway that 
regulates transcription of Gabra1 in neurons.  
 We hypothesized that an association between JAK2, a cytokine signaling 
molecule, and a neurotrophin receptor could occur in response to BDNF 
signaling and that such interaction would happen at the cell membrane. Like 
neurotrophin receptors, cytokine receptors bind to their ligands as dimers, which 
helps to activate JAK proteins by bringing them in close proximity. The 
neurotrophin receptor p75NTR is also known to form a dimer with a number of 
different proteins and receptors. It is therefore possible that BDNF induces 
activation of JAK/STAT signaling by binding its receptor, which recruits JAK 
protein. Results from our Co-IP studies in both primary neurons (Figure 5B) and 
HEK (Figure 5C), and mutational analysis in HEK (Figure 6), reveal a novel 
association between full-length p75NTR and JAK2. Interestingly, JAK2 does not 
associate with TrkB, and p75NTR also associates with STAT3 (Figure 5B). 
Furthermore, the presence of pJAK2 in samples precipitated with an anti-
p75NTR antibody was found to increase in primary neurons following stimulation 
with BDNF (Figure 5A), as would be expected for traditional JAK/STAT signaling 
through a growth factor. To our surprise, however, when we used confocal 
microscopy to localize the complex in neurons we found that it was 
predominantly in cytoplasm, then nucleus, and processes (Figures 7 and 8).  
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 One of the assumptions made from our studies is the potential use of 
JAK/STAT inhibitors in the treatment of epilepsy. There are many JAK/STAT 
inhibitors on the current market, with most being used to treat forms of cancer. 
Collaborative studies in our laboratories have looked at JAK/STAT inhibition in 
the pilocarpine-induced SE rat, and found WP1066, an inhibitor of JAK2 and 
STAT3, (also STAT5 and ERK1/2) reduces the frequency of spontaneous 
seizures (Grabenstatter et al., 2014). We now show that WP1066 inhibits 
JAK/STAT through degradation of JAK2 (Figure 9A). Interestingly, ruxolitinib 
(RUXO), an inhibitor of JAK/STATs currently used in the clinical treatment of 
myeloproliferative neoplasms (Mascarenhas and Hoffman, 2012), does not 
degrade JAK2 (Figure 9B), but potently blocks pSTAT3 (Figure 10A). 
Furthermore, the complex of JAK2:eGFP and p75NTR-Flag in HEK was 
disturbed when neurons were treated with RUXO both in cultured neurons (using 
PLA, Figure 10C) and in transfected HEK cells (Figure 10B). Further studies 
using JAK/STAT inhibitors will help to not only understand the mechanism of 
JAK/STAT activation through BDNF, but could also help discover potential 
therapeutics for epilepsy. 
 Our results from fluorescence microscopy suggest that an endogenous 
association between JAK2 and p75NTR occurs specifically in these cellular 
compartments (Figures 7 and 8). Because of the predominantly cytoplasmic 
localization of the JAK2/p75NTR complex, we have referred to it as the 
signalsome (i)p75NTRJ2. At this time, we have not found evidence to link 
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association of JAK2 to p75NTR at the plasma membrane, although we can not 
rule out that (i)p75NTRJ2 gets trafficked to the membrane at some point for 
coupling with downstream effectors. In addition, whether or not (i)p75NTRJ2 can 
be activated by intracellular BDNF also remains a mystery especially fueled by 
our promoter studies and the fact that intracellular levels of BDNF rise in SE. 
 Studies have found that neurons increase their levels of matBDNF 
mRNAs in response to chronic matBDNF treatment in culture, suggesting that 
intracellular levels of matBDNF may be high during brain insult (Greenberg et al., 
2009). Recent studies have also found that proBDNF levels are elevated in the 
hippocampus of pilocarpine-induced SE mice very quickly (Thomas et al., 2016). 
This increase in intracellular levels of BDNF may have a number of downstream 
effects that could contribute to the development of epilepsy. Indeed, in our 
studies in primary neuron cultures, overexpression of the full-length, translated 
form of BDNF (non-mutated proBDNF) caused decreased promoter activity at 
GABRA1, which is consistent with findings that seizure activity leads to 
downregulation GABAAR subunit α1. These results suggest that intracellular 
BDNF levels may be a driving factor in changes in gene expression that occur in 
epilepsy. It is possible that BDNF at the cell surface activates TrkB, leading to 
increased BDNF transcription via MAPK activation of CREB, increasing 
intracellular BDNF. The intracellular BDNF could activate an intracellular BDNF 
receptor coupled to JAK/STAT activation that turns on ICER and turns off 
GABRA1.  
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B. LSF is a novel target of BDNF signaling. 	
 LSF acts as a cell cycle regulator in many different cell types and its 
dysregulation can lead to oncogenesis and unchecked cellular proliferation 
(Grant et al., 2012). Its role in neurons, however, has yet to be characterized 
beyond its potential involvement in APP-mediated cell survival (Kashour et al., 
2003). Since neurons do not readily divide throughout their lifetime, and cell cycle 
regulators are involved in neuronal maturation, migration, and synaptic plasticity 
(Frank and Tsai, 2009; Lim and Kaldis, 2013), LSF likely plays a unique role in 
the brain. Neurogenesis occurs throughout brain development, and to a lesser 
extent through adulthood in three brain regions: the subgranular zone (SGZ), 
subventricular zone (SVZ), and the olfactory neuroepithelia. Adult neurogenesis 
is closely linked to seizure activity, given that seizure activity leads to aberrant 
hippocampal neurogenesis characterized by increased proliferation of neural 
progenitors, although whether this leads to more or fewer new neurons is under 
question (Sierra et al., 2015). The results of our study now suggest that a specific 
phosphorylated form of LSF, p291, is present in select neuronal populations and 
may be linked to seizure activity and neuron fate.  
 Our present studies in vitro with protein extracts from primary neuronal 
cultures found that BDNF signaling induces phosphorylation of LSF specifically at 
serine 291, an effect that is blocked with the MEK inhibitor, U0126. General 
depolarization of neurons through KCl treatment did not produce the same effect, 
suggesting that BDNF signaling regulates LSF activity through selective 
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phosphorylation at this residue. Studies from the literature with non-neuronal cell 
types show that mitogenic stimulation causes quick (five minutes) 
phosphorylation at serine 291 and later (one to two hours) phosphorylation at 
serine (Pagon et al., 2003; Saxena et al., 2009). In our studies with primary 
neuronal cultures, however, BDNF stimulation for four hours selectively 
phosphorylates serine 291, while there is no effect on phosphorylation of serine 
309. These results suggest that phosphorylation at serine 291 of LSF may be a 
neuron-specific post-translational modification that BDNF uses to move them into 
the mature state. Because of this BDNF specificity, we chose to focus on p291 
LSF rather than p309 for our examination of LSF in developing neurons.    
 The protein band pattern in p291 LSF western blots from our primary 
neuron cultures show a ladder of bands of slower moving, larger sized protein 
species. These bands may represent SUMOylation of LSF, which has been 
reported in response to heat shock (Golebiowski et al., 2009). This intensity of 
the bands increases with BDNF treatment and is specific to p291 LSF blots, 
since it is seen not in p309 LSF or total LSF blots. SUMOylation is a major 
regulator of neuronal processes, including protein trafficking, neuronal 
differentiation, synapse formation, and cell survival (reviewed by Henley et al., 
2014). It is possible that SUMOylation may be an important step in the neuronal 
function of LSF. Future experiments should work to determine if these bands are 
indeed SUMOylated LSF. 
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It is well established that SE leads to alterations in subunit composition of 
the type A GABA receptor (Brooks-Kayal et al., 1998b) and that BDNF 
transcriptionally regulates expression of two subunits, α4 and α1. BDNF activates 
TrkB and MAPK signaling to regulate synthesis of Egr3, leading to increased α4 
subunit levels (Roberts et al., 2005) and also activates JAK/STAT signaling 
through TrkB (revision in preparation Hokenson et al. 2015) leading to STAT3-
mediated synthesis (Lund et al., 2008). To determine whether JAK/STAT 
signaling contributes to the rise in BDNF-induced p291 LSF levels, cultures were 
pre-treated with P6, a pan-JAK inhibitor prior to BDNF stimulation. P6 did not 
block BDNF-induced phosphorylation of LSF at serine 291, suggesting that p291 
LSF phosphorylation may be part of the signaling cascade that affects 
downstream α4 subunit levels rather than α1. Future studies should address 
whether phosphorylation of LSF at serine 291 affects GABAR subunit expression 
in dentate granule cells of seizure susceptible rats. 
 While BDNF treatment of primary neuronal cultures in vitro is a limited 
molecular model of epilepsy, it is hard to draw conclusions about epileptogenesis 
in vivo. These results, however, do suggest that LSF is an attractive target for 
future research using animal models of TLE. As a first step to link LSF 
phosphorylation to epileptogenesis, we used an in vivo pilocarpine-induced SE 
rodent model to assess whether p291 LSF levels increase upon SE, as seen in 
culture after BDNF treatment. We found that hippocampal protein extracts from 
SE animals do indeed contain increased levels of p291 when compared to 
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controls. We hypothesize that this increase in p291 levels is a result of increased 
levels of BDNF known to occur in the hippocampus of SE animals and 
specifically associated with the process of epileptogenesis.  
  In addition, we found that total, p291, and p309 LSF, are all expressed in 
NeuN-positive neurons. Due to the ubiquitous expression of LSF, it is not 
surprising that total LSF is present in neurons. Interestingly, the majority of total 
LSF staining appears to be contained within the nucleus or soma of the neuron, 
the expected localization for a transcription factor, while p291 and p309 LSF also 
appear in neuronal processes. It is therefore possible that phosphorylated forms 
of LSF may play another role in neuronal cell types or that phosphorylation may 
be linked to activities occurring at a distance from the soma. It is also possible 
that phosphorylated forms, which are inhibitory of LSF activity, may keep LSF 
outside of the nucleus, where is it most active.  
 Absence or barely detectable levels of p291 LSF in EdU-positive, dividing 
neurons is consistent with findings in non-neuronal cells types that 
phosphorylation of LSF at serine 291 occurs in early G1 and dephosphorylates at 
the end of G1, before entering S phase (Pagon et al., 2003). EdU incorporates 
into cells during S phase of the cell cycle, at a point when LSF has been 
desphosphorylated. However, BDNF is known to promote neurogenesis and so it 
would be expected that more EdU positive cells would accompany the increase 
in p291 LSF, as seen in our primary cultured neurons. This does not seem to be 
the case, at least on an individual cell basis, in our studies, and suggests that 
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BDNF may promote neurogenesis by stabilizing the mature neuronal state by 
increasing the number of neurons detected rather than producing more precursor 
cells. We also saw cells that only stained for DAPI, but did not stain for LSF or 
any marker we used. Future studies will aim to characterize these populations. 
 Our immunocytochemistry studies with neuronal maturation markers 
suggest that p291 LSF may persist throughout neurogenesis, with the highest 
levels are greatest in newly generated neurons (PSA-NCAM positive) and those 
with a post-mitotic and mature phenotype (MAP2 positive). We did not look, 
however, at neurons beyond seven days in vitro, where they may still be 
undergoing differentiation, so at this time we do not know if p291 expression 
persists after neurons age. Future studies with older primary cultures, where 
MAP2 is persistently detected, will be needed to determine if p291 LSF plays a 
role in maintaining a post-mitotic cellular state over time. The results of our 
studies, while suggestive that p291 LSF may have a long-term role in post-mitotic 
neurons of the brain, rather than a short-term regulation of the cell cycle, is 
attractive, however, its presence in neurons may be an indication of its role as an 
effector of neuronal fate rather than maintenance. This is consistent with our 
studies of the adult rat brain regions, which show further correlation between high 
levels of p291 LSF and areas containing newly generated neurons or undergoing 
persistent neurogenesis when compared to those with low neurogenesis.   
 It is possible that phosphorylation of LSF at serine 291 occurs at a certain 
point during neurogenesis, like a switch that turns on after cell division. Based on 
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our markers of cell proliferation and different stages of neuronal maturation, we 
can predict that p291 LSF is turned off during proliferation and turns on when 
cells are differentiating. 
 In what appears to be an additional paradox, p291 LSF levels are 
increased in the hippocampus of animals with epilepsy, where increased 
neurogenesis is expected. It is possible, however, that the increase in p291 LSF 
reflects the greater number of post-mitotic cells that occur as a result of 
increased neurogenesis. In our TLE model, hippocampal dissections are 
performed twenty-four hours after SE induction, where there is plenty of time for 
aberrant neurogenesis to produce a substantial increase in post-mitotic neurons. 
In future studies, it may help to look at how p291 LSF protein levels change at a 
longer time point after SE, in animals with chronic epilepsy, where neurogenesis 
is decreased. It would be interesting to see if LSF phosphorylation at serine 291 
causes the same abherrant neurogenesis seen after seizure activity in the 
hippocampus, such as increased proliferation of neural progenitors, production of 
EGCs, MFS, DGC layer dispersion, neuronal hypertrophy and persistence of 
hilar basal dendrites on adult-generated granule neurons (Parent et al., 1997; 
Scharfman, 2002; Pun et al., 2012). 
 It is also possible that p291 LSF is involved in abortive cell cycle re-entry, 
in which the initial insult of SE could cause upregulation of cell cycle markers and 
attempted cell cycle re-entry (Becker and Bonni, 2004; Liu and Greene, 2001). In 
this case, neurons may specifically show in upregulation in p291 LSF, rather than 
		150	
total LSF or p309 LSF, the result of which may lead to neuronal cell death. It 
would be worth investigating if LSF is one of the cell cycle regulators involved in 
neuronal abortive cell cycle re-entry, and specifically if phosphorylation of LSF 
occurs in such states.  
Increased expression of the Notch intracellular domain 1 (NICD1) and LSF 
protein have been reported in liver cancer tissue from human 
hepatocarcinogenesis and an upregulation of LSF protein has been reported in 
cells overexpressing Notch1 supported by a role for LSF in Notch synthesis and 
regulation (Fan et al., 2011). Notch genes also encode for heterodimeric 
transmembrane receptors that help regulate cell proliferation, differentiation, and 
apoptosis (Artavanis-Tsakonas et al., 1999; Osborne and Miele, 1999) and 
aberrant Notch signaling may contribute to carcinogenesis (Weijzen et al., 2002). 
Interestingly, Notch signaling is also important in the central nervous system, 
where it helps maintain neural stem cells, determine cell fate, and regulate 
neurite outgrowth in post-mitotic neurons (Ables et al., 2011; Pierfelice et al., 
2011). Sha et al (2014) found persistently elevated levels of both Notch1 and 
NICD1 post-SE in a kainic acid (KA) mouse model of TLE, and activation of 
Notch signaling increased seizure frequency. Importantly, increased NICD1 
protein levels are found in the sclerotic hippocampus from mesial temporal lobe 
epilepsy (MTLE) patients compared to controls and Notch signaling is required to 
maintain neural stem cells (NSCs) in the adult brain (Pierfelice et al., 2011) and 
to drive differentiation towards a post-mitotic state (Chapouton et al., 2010). We 
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hypothesize that BDNF-induced phosphorylation of LSF at serine 291 in culture 
and after SE may influence Notch signaling, and is an area of investigation that 
would be of interest in future studies. 
Further study into the mechanism underlying the phosphorylation and 
regulation of LSF in response to seizure activity is worthwhile, due to the 
availability of a small molecule inhibitor of LSF, FQI1. LSF inihibition has been 
shown to reduce tumor growth and cytotoxicity (Grant et al., 2012) and may also 
serve a dual purpose in the prevention or reduction of the effects of seizure 
activity in the brain.  
C. New Therapeutic Directions in the Treatment and Prevention of Epilepsy 
 The development of new therapeutics for epilepsy is important, given that 
one-third of epilepsy cases are refractory and don’t respond to current AEDs 
(French et al., 2013). Current drugs also treat the symptomatic seizures of 
epilepsy, rather than the underlying mechanisms of the disease (Loscher and 
Schmidt, 2011). One major challenge to the treatment of epilepsy is about 40% 
of epilepsy cases result from an insult and could be prevented (Banerjee et al., 
2009), but not all brain injuries lead to the development of epilepsy (Annegers et 
al., 1998). Studies in our lab and others suggest that use of BDNF receptor 
antagonists or intracellular pathway regulators may be effective for epilepsy 
treatments.  
 The JAK/STAT signaling pathway may be a good target for epilepsy 
treatment. Collaborative studies in our lab have shown that the JAK/STAT 
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pathway is activated upstream of changes in GABAAR subunit expression (Lund 
et al., 2008), and in vivo treatment with a STAT3 inhibitor in rats with SE 
alleviated seizures (Grabenstatter et al., 2014). Use of drugs that are already on 
the market, or development of more efficacious JAK/STAT inhibitors may help 
refractory forms of epilepsy. 
 While BDNF and epilepsy are closely linked, targeting BDNF for anti-
epileptic therapeutics has proved to be more complicated. Based on our findings, 
we would assume reducing levels of BDNF would alleviate epilepsy, however, 
studies show that continuous administration of low dose BDNF (200-300 pg per 
hour) in a kainic acid model of epilepsy amelioriated seizure activity (Kuramoto et 
al., 2011). It is possible that low doses of BDNF downregulate TrkB receptors. 
Paradiso and colleagues (Paradiso et al., 2009) used a replication-defective 
herpes simplex virus-1 (HSV-1) vector to deliver BDNF and fibroblast growth 
factor-2 (FGF-2) into the hippocampus of rats 4 days after SE onset, and while 
they found signs of aberrant neurogenesis, there was a reduction in spontaneous 
recurrent seizures. The mechanism of action for this is difficult to know, since 
treatment was given after epileptogenesis. BDNF application may be difficult to 
use due to the mechanistic changes in response and therefore intracellular 
pathway. We want to understand the surface of the interaction between JAK2 
and p75NTR and to disturb the interaction as a novel antagonist.  
 Many experiments inhibiting BDNF activity have targeted its receptor, 
TrkB, with novel antagonists (McNamara and Scharfman, 2012). TrkB may be a 
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better target, since treatment of mouse TLE model with a novel peptide, pY816, 
which uncouples TrkB from its dominant effector phospholipase Cγ1, has an anti-
epileptic effect (Gu et al., 2015). There was also a reported anxiolytic effect, 
which was also seen in mice treated with a TrkB inhibitor, cyclotraxin-B (Cazorla 
et al., 2010). Given that BDNF and TrkB are important for long-term potentiation 
(LTP), neuronal survival, and axonal growth (Minichiello et al., 1999; Xu et al., 
2000), targeting TrkB may lead to negative side effects. Interestingly, studies 
have revealed that treatment with AEDs phenytoin and lamotrigine cause 
decreased levels of serum BDNF (Soysal et al., 2015). There is clearly a 
causative relationship between increased levels of BDNF and epileptogenesis 
(Scharfman, 2005), but how to target this pathway for the development of 
efficacious therapeutics is unknown and is of great interest to our laboratory. 
D. Conclusions and Future Directions 	
 We show that BDNF signals through a TrkB-mediated p75NTR/JAK2 
signaling pathway to induce ICER expression as relevant to the control of α1-
containing GABAARs. Through our detailed characterization of this pathway, we 
hope to identify novel targets to test as future therapeutics for the treatment 
and/or cure of epilepsy, as well as other disorders of the nervous system where 
an alteration in BDNF signaling and GABAR expression has been associated. 
Taken together, these studies propose a potential mechanism by which BDNF 
activates the JAK/STAT pathway in neurons, an active area of investigation given 
the role of TrkB, p75NTR and JAK/STATs in normal processes of learning and 
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memory (Bibel and Barde, 2000; Korte et al., 1995; Korte et al., 1996; Zigova et 
al., 1998; Nicolas et al., 2012). 
Our data strongly suggest that specific phosphorylation of a cell cycle 
regulator, at serine 291 of LSF, occurs in response to BDNF signaling and in an 
animal model of status epilepticus. It is likely that BDNF signaling regulates LSF 
activity through phosphorylation at serine 291. Elevated levels of p291 LSF are in 
the hippocampus of SE animals, and may be a result of increased BDNF from 
seizure activity. The phosphorylation of LSF at serine 291 may also play a role in 
neurogeneis, given that expression occurs throughout the stages of neurogensis. 
The relationship between adult neurogenesis and p291 LSF suggests a more 
complex role for BDNF in the production of neuronal populations in the normal 
and diseased brain. Whether this phosphorylation of LSF is an adaptive 
response to help produce new neurons or a part of the disease pathology 
requires further study. 
In summary, we were able to further elucidate the previously studied link 
between the neurotrophin BDNF and cytokine signaling of JAK/STATs, and 
identified the cell cycle regulation of LSF as a novel target of BDNF signaling. 
Continued study of both these pathways will help to further understand the 
mechanisms underlying the development of epilepsy and provide new targets for 
therapeutic intervention.  
We propose that induction of BDNF after SE binds to and activates TrkB, 
leading to downstream activation of signaling pathways, including JAK/STAT 
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phosphorylation and MAPK signaling. JAK/STATs form a complex with p75NTR, 
either separate complexes of JAK2 and p75NTR, p75NTR and STAT3, or 
potentially in a complex containing JAK2, STAT3, and p75NTR. Along with 
JAK/STAT activation of pCREB, which binds with ICER to inhibit Gabra1 
expression, the complex of p75NTR/JAK2 may also translocate to the nucleus 
and induce changes in gene expression. Activation of MAPK signaling, which 
leads to Egr3 binding and inducing expression of Gabra4, can also cause 
phosphorylation of LSF at serine 291, and potentially mediate cell fate. Increases 
in intracellular proBDNF caused by SE, may enhance the formation of a 
p75NTR/JAK2 complex and promote inhibition of Gabra1 expression (see figure 
below). 
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Figure 21: Schematic of proposed cellular responses to SE and 
BDNF signaling  
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VI. APPENDIX 
A1. Dark-exposure decreases GABAR δ subunit levels in visual cortex of 
mice.  
Data contributed to:  
Huang, S., Hokenson, K., Bandyopadhyay, S., Russek, S.J., and Kirkwood, A. 
(2015) Brief Dark Exposure Reduces Tonic Inhibition in Visual Cortex. Journal of 
Neuroscience. 35, 15916-15920.  
 
 
 
 
Figure 1A: Brief dark exposure (2-day, starting at P21–P22) selectively 
decreases GABAR δ subunit levels, but not γ2 or α1 subunit levels, in 
visual cortex. Shown are the results of Western blot analysis of δ (A), α1 (B), 
and γ2 (C) subunit expression levels as sampled in the visual cortex (VC) and 
frontal cortex (FC) of normal-reared (NR) and dark-exposed (DE) mice. The bars 
indicate the average normalized intensity values for the three subunits in NR 
(open bars, n = 9 mice) and DE (filled bars, n = 10 mice) mice. *p < 0.05. 
Example blots are shown on top. 
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